



AL


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, C12N 15/12, 5/10, C12Q 1/68, A61K 38/17		A2	(11) International Publication Number: WO 98/17687
			(43) International Publication Date: 30 April 1998 (30.04.98)
(21) International Application Number: PCT/US97/19590		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 October 1997 (24.10.97)		Published Without international search report and to be republished upon receipt of that report.	
(30) Priority Data: 08/740,274 25 October 1996 (25.10.96) US Not furnished 24 October 1997 (24.10.97) US			
(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).			
(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 90 Green Meadow Drive, Tewksbury, MA 01876 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US).			
(74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).			

(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

(57) Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.



Plasmid name: pED8dpc2
Plasmid size: 5374 bp

Comments/References: pED8dpc2 is derived from pED8dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4483-4490.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10

15 **SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM**

 This application is a continuation-in-part of application Ser. No. 08/740,274, filed October 25, 1996.

20

FIELD OF THE INVENTION

 The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

25

BACKGROUND OF THE INVENTION

 Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly
30 related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning
35 techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

40

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 437 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 515 to nucleotide 1159;
- 10 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 539 to nucleotide 1099;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AR415_4 deposited under accession number ATCC 98232;
- 15 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AR415_4 deposited under accession number ATCC 98232;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AR415_4 deposited under accession number ATCC 98232;
- 20 (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AR415_4 deposited under accession number ATCC 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
- 25 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- 30 (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 437 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:1 from nucleotide 515 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:1 from

nucleotide 539 to nucleotide 1099; the nucleotide sequence of the full-length protein coding sequence of clone AR415_4 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone AR415_4 deposited under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AR415_4 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 51 to amino acid 221.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) the amino acid sequence of SEQ ID NO:2 from amino acid 51 to amino acid 221;
- (c) fragments of the amino acid sequence of SEQ ID NO:2; and
- (d) the amino acid sequence encoded by the cDNA insert of clone

AR415_4 deposited under accession number ATCC 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid 51 to amino acid 221.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 59 to nucleotide 376;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 179 to nucleotide 376;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AS63_29 deposited under accession number ATCC 98232;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AS63_29 deposited under accession number ATCC 98232;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AS63_29 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AS63_29 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 59 to nucleotide 376; the nucleotide sequence of SEQ ID NO:3 from nucleotide 179 to nucleotide 376; the nucleotide sequence of the full-length protein coding sequence of clone AS63_29 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone AS63_29 deposited under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AS63_29 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 91.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3 or SEQ ID NO:5.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 91;

(c) fragments of the amino acid sequence of SEQ ID NO:4; and

(d) the amino acid sequence encoded by the cDNA insert of clone

5 AS63_29 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 91.

In one embodiment, the present invention provides a composition comprising an
10 isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 198 to nucleotide 2039;

15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 490 to nucleotide 809;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AY304_14 deposited under accession number ATCC xxxxx;

20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AY304_14 deposited under accession number ATCC xxxxx;

25 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;

30 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:6 from nucleotide 198 to nucleotide 2039; the nucleotide sequence of SEQ ID NO:6 from nucleotide 490 to nucleotide 809; the nucleotide sequence of the full-length protein coding sequence of clone AY304_14 deposited under accession number ATCC xxxxx; or the nucleotide sequence of the mature protein coding sequence of clone AY304_14 deposited under accession number ATCC xxxxx. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7 from amino acid 126 to amino acid 204 or a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7 from amino acid 106 to amino acid 204.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:6.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:7;
- (b) the amino acid sequence of SEQ ID NO:7 from amino acid 126 to amino acid 204;
- (c) the amino acid sequence of SEQ ID NO:7 from amino acid 106 to amino acid 204;
- (d) fragments of the amino acid sequence of SEQ ID NO:7; and
- (e) the amino acid sequence encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:7; the amino acid sequence of SEQ ID NO:7 from amino acid 126 to amino acid 204; or the amino acid sequence of SEQ ID NO:7 from amino acid 106 to amino acid 204.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 102 to nucleotide 2027;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 1902 to nucleotide 2027;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 1 to nucleotide 431;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited under accession number ATCC 98232;
- 10 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BG160_1 deposited under accession number ATCC 98232;
- 15 (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
- 20 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 25 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:8 from nucleotide 102 to nucleotide 2027; the nucleotide sequence of SEQ ID NO:8 from nucleotide 1902 to nucleotide 2027; the nucleotide sequence of SEQ ID NO:8 from nucleotide 1 to nucleotide 431; the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone BG160_1 deposited

30

under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein
5 comprising the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 110.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:8.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
10 consisting of:

- (a) the amino acid sequence of SEQ ID NO:9;
- (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 110;
- (c) fragments of the amino acid sequence of SEQ ID NO:9; and
- 15 (d) the amino acid sequence encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:9 or the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 110.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
25 NO:11 from nucleotide 566 to nucleotide 631;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO432_4 deposited under accession number ATCC 98232;
- (d) a polynucleotide encoding the full-length protein encoded by the
30 cDNA insert of clone BO432_4 deposited under accession number ATCC 98232;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BO432_4 deposited under accession number ATCC 98232;

- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BO432_4 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- 5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein
- 10 of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 566 to nucleotide 631; the nucleotide sequence of the full-length

15 protein coding sequence of clone BO432_4 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone BO432_4 deposited under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BO432_4 deposited under accession number ATCC 98232.

20 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11, SEQ ID NO:10 or SEQ ID NO:13 .

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 25 (a) the amino acid sequence of SEQ ID NO:12;
- (b) fragments of the amino acid sequence of SEQ ID NO:12; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BO432_4 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such

30 protein comprises the amino acid sequence of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14 from nucleotide 45 to nucleotide 428;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO538_2 deposited under accession number ATCC 98232;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BO538_2 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:15 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:14 from nucleotide 45 to nucleotide 428; the nucleotide sequence of the full-length protein coding sequence of clone BO538_2 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone BO538_2 deposited under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15 from amino acid 52 to amino acid 128.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:14 or SEQ ID NO:16.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:15;
- 5 (b) the amino acid sequence of SEQ ID NO:15 from amino acid 52 to amino acid 128;
- (c) fragments of the amino acid sequence of SEQ ID NO:15; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232;
- 10 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:15 or the amino acid sequence of SEQ ID NO:15 from amino acid 52 to amino acid 128.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 144 to nucleotide 566;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BR595_4 deposited under accession number ATCC 98232;
- 20 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BR595_4 deposited under accession number ATCC 98232;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BR595_4 deposited under accession number ATCC 98232;
- 25 (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BR595_4 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- 30 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 144 to nucleotide 566; the nucleotide sequence of the full-length protein coding sequence of clone BR595_4 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone BR595_4 deposited under accession number ATCC 98232. In other preferred embodiments, the
10 polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BR595_4 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18 from amino acid 39 to amino acid 141.

15 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17 or SEQ ID NO:19.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:18;
(b) the amino acid sequence of SEQ ID NO:18 from amino acid 39 to amino acid 141;
(c) fragments of the amino acid sequence of SEQ ID NO:18; and
(d) the amino acid sequence encoded by the cDNA insert of clone
25 BR595_4 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18 or the amino acid sequence of SEQ ID NO:18 from amino acid 39 to amino acid 141.

30 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 232 to nucleotide 1041;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 460 to nucleotide 1041;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 590 to nucleotide 1163;
- 5 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI490_2 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI490_2 deposited under accession number ATCC 98232;
- 10 (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CI490_2 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CI490_2 deposited under accession number ATCC 98232;
- 15 (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 20 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
- 25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 232 to nucleotide 1041; the nucleotide sequence of SEQ ID NO:20 from nucleotide 460 to nucleotide 1041; the nucleotide sequence of SEQ ID NO:20 from nucleotide 590 to nucleotide 1163; the nucleotide sequence of the full-length protein coding sequence of clone CI490_2 deposited under accession number ATCC 98232; or the
- 30 nucleotide sequence of the mature protein coding sequence of clone CI490_2 deposited under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CI490_2 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein

comprising the amino acid sequence of SEQ ID NO:21 from amino acid 133 to amino acid 270.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:20.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:21;
- (b) the amino acid sequence of SEQ ID NO:21 from amino acid 133 to
10 amino acid 270;
- (c) fragments of the amino acid sequence of SEQ ID NO:21; and
- (d) the amino acid sequence encoded by the cDNA insert of clone
CI490_2 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such
15 protein comprises the amino acid sequence of SEQ ID NO:21 or the amino acid sequence of SEQ ID NO:21 from amino acid 133 to amino acid 270.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
20 NO:22;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:22 from nucleotide 268 to nucleotide 624;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:22 from nucleotide 325 to nucleotide 624;
- (d) a polynucleotide comprising the nucleotide sequence of the full-
25 length protein coding sequence of clone CI522_1 deposited under accession
number ATCC 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the
cDNA insert of clone CI522_1 deposited under accession number ATCC 98232;
- (f) a polynucleotide comprising the nucleotide sequence of the mature
30 protein coding sequence of clone CI522_1 deposited under accession number
ATCC 98232;
- (g) a polynucleotide encoding the mature protein encoded by the
cDNA insert of clone CI522_1 deposited under accession number ATCC 98232;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:23;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:23 having biological activity;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

10 (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:22 from nucleotide 268 to nucleotide 624; the nucleotide sequence of SEQ ID NO:22 from nucleotide 325 to nucleotide 624; the nucleotide sequence of the full-length protein coding sequence of clone CI522_1 deposited under accession number ATCC 98232; or the
15 nucleotide sequence of the mature protein coding sequence of clone CI522_1 deposited under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CI522_1 deposited under accession number ATCC 98232.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
20 ID NO:22 or SEQ ID NO:24.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 25 (a) the amino acid sequence of SEQ ID NO:23;
(b) fragments of the amino acid sequence of SEQ ID NO:23; and
(c) the amino acid sequence encoded by the cDNA insert of clone CI522_1 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:23.

30 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 288 to nucleotide 713;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 686 to nucleotide 968;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CN238_1 deposited under accession number ATCC 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232;
- 10 (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CN238_1 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of
- 20 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 288 to nucleotide 713; the nucleotide sequence of SEQ ID NO:25 from nucleotide 686 to nucleotide 968; the nucleotide sequence of the full-length protein coding sequence of clone CN238_1 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone CN238_1 deposited
- 30 under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232.
- Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:26;
- 5 (b) fragments of the amino acid sequence of SEQ ID NO:26; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26.

- 10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 87 to nucleotide 1874;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 452 to nucleotide 830;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO390_1 deposited under accession number ATCC 98232;
- 20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CO390_1 deposited under accession number ATCC 98232;
- 25 (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
- 30 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 87 to nucleotide 1874; the nucleotide sequence of SEQ ID NO:27 from nucleotide 452 to nucleotide 830; the nucleotide sequence of the full-length protein coding sequence of clone CO390_1 deposited under accession number ATCC 98232; or the nucleotide sequence of the mature protein coding sequence of clone CO390_1 deposited
10 under accession number ATCC 98232. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28 from amino acid 140 to amino acid
15 248.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
20 consisting of:

- (a) the amino acid sequence of SEQ ID NO:28;
- (b) the amino acid sequence of SEQ ID NO:28 from amino acid 140 to amino acid 248;

- (c) fragments of the amino acid sequence of SEQ ID NO:28; and
- 25 (d) the amino acid sequence encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28 from amino acid 140 to amino acid 248.

30 In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 is a schematic representation of the pED6 and pNOTs vectors used for deposit of clones disclosed herein.

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell

in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Clone "AR415_4"

5 A polynucleotide of the present invention has been identified as clone "AR415_4". AR415_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AR415_4 is a full-length
10 clone, including the entire coding sequence of a secreted protein (also referred to herein as "AR415_4 protein").

The nucleotide sequence of AR415_4 as presently determined is reported in SEQ ID NO:1. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AR415_4 protein corresponding to the foregoing
15 nucleotide sequence is reported in SEQ ID NO:2. Amino acids 14 to 26 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AR415_4 should be approximately 1500 bp.

20 The nucleotide sequence disclosed herein for AR415_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AR415_4 demonstrated at least some homology with sequences identified as AA100799 (zm26d01.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 526753 3'), AA100852 (zm26d01.r1 Stratagene pancreas (#937208) Homo sapiens
25 cDNA clone 526753 5' similar to SW CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA146605 (zo35c09.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 588880 5' similar to SW:CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA224847 (nc33c12.s1 NCI CGAP Pr2 Homo sapiens cDNA clone 4079 similar to SW:CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029),
30 AA225191 (nc21h08.s1 NCI CGAP Pr1 Homo sapiens cDNA clone 2968), AA593864 (nn19f08.s1 NCI_CGAP_Co12 Homo sapiens cDNA clone IMAGE:1084359), D26483 (Mouse mRNA for PE31/TALLA. 3/), M33680 (Human 26-kDa cell surface protein TAPA-1 mRNA, complete cds), T14726 (Human CD53 antigen cDNA), and T23814 (Human gene signature HUMGS05723). The predicted amino acid sequence disclosed

herein for AR415_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AR415_4 protein demonstrated at least some identity with sequences identified as D29808 (TALLA-1 [Homo sapiens]), M35252 (tumor-associated antigen [Homo sapiens]), and R22360 (CO-029 tumour associated antigen protein). Based upon homology, AR415_4 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the AR415_4 protein sequence centered around amino acid 100 of SEQ ID NO:2.

10 Clone "AS63_29"

A polynucleotide of the present invention has been identified as clone "AS63_29". AS63_29 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AS63_29 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AS63_29 protein").

The nucleotide sequence of the 5' portion of AS63_29 as presently determined is reported in SEQ ID NO:3. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:4. The predicted amino acid sequence of the AS63_29 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 28 to 40 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of AS63_29, including the polyA tail, is reported in SEQ ID NO:5.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AS63_29 should be approximately 1700 bp.

The nucleotide sequence disclosed herein for AS63_29 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AS63_29 demonstrated at least some homology with sequences identified as L26877 (Mus musculus (B20c) heavy chain immunoglobulin variable region gene), T09146 (EST07039 Homo sapiens cDNA clone HIBBP68 5' end), T23466 (seq3050 Homo sapiens cDNA clone Hy18-Ch13-Charon40-cDNA-100 3'), and W55739 (ma35f05.r1 Life Tech mouse brain Mus musculus cDNA clone 312705 5'). The predicted amino acid

sequence disclosed herein for AS63_29 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AS63_29 protein demonstrated at least some identity with sequences identified as R04032 (Full length T4 encoded by plasmid pBG381). Based upon homology, AS63_29 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the AS63_29 protein sequence, near the amino terminus.

Clone "AY304_14"

A polynucleotide of the present invention has been identified as clone "AY304_14". AY304_14 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AY304_14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AY304_14 protein").

The nucleotide sequence of AY304_14 as presently determined is reported in SEQ ID NO:6. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AY304_14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:7.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AY304_14 should be approximately 2200 bp.

The nucleotide sequence disclosed herein for AY304_14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AY304_14 demonstrated at least some homology with sequences identified as AA127688 (zk92f05.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 490305 3'), AA179609 (zp49g11.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 612836 5'), AA276253 (vc40f05.r1 Barstead MPLRB1 Mus musculus cDNA clone 777057 5'), H15545 (ym27d04.s1 Homo sapiens cDNA clone 49495 3' similar to contains PTR5 repetitive element), L08441 (Human autonomously replicating sequence (ARS) mRNA), N34949 (yy49h09.s1 Homo sapiens cDNA clone 276929 3'), R48594 (yj65d07.s1 Homo sapiens cDNA clone 153613 3'), T21160 (Human gene signature HUMGS02466), U43284 (Cloning vector pHGF-S65T, complete sequence, green fluorescent protein (gfp) gene, complete cds), and Z45151 (H. sapiens partial cDNA

sequence; clone c-2hh04). The predicted amino acid sequence disclosed herein for AY304_14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AY304_14 protein demonstrated at least some identity with sequences identified as D86984 (similar to yeast adenylate cyclase (S56776) [Homo sapiens]), J01415 (cytochrome oxidase subunit 3 [Homo sapiens]), V00662 (cytochrome oxidase III [Homo sapiens]), and X68948 (envelope glycoprotein [Spleen focus-forming virus]). Based upon homology, AY304_14 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the AY304_14 protein sequence, one centered around amino acid 81 and another around amino acid 120 of SEQ ID NO:7.

Clone "BG160_1"

A polynucleotide of the present invention has been identified as clone "BG160_1". BG160_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG160_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG160_1 protein").

The nucleotide sequence of BG160_1 as presently determined is reported in SEQ ID NO:8. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG160_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:9. Amino acids 588 to 600 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 601, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG160_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for BG160_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG160_1 demonstrated at least some homology with sequences identified as A60021 (tropomyosin-related protein, neuronal - rat ;contains element MER27 repetitive element), AA081525 (zn20e02.r1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 547994 5'), AA092565 (II5773.seq.F Fetal heart, Lambda ZAP Express Homo sapiens cDNA 5'), D56138 (Human fetal brain cDNA 5'-end

GEN-416H11), D61090 (Human fetal brain cDNA 5'-end GEN-155A07), D61184 (Human fetal brain cDNA 5'-end GEN-165A01), L10335 (Homo sapiens neuro-endocrine-specific protein C (NSP) mRNA, complete cds), N21304 (yx53f07.s1 Homo sapiens cDNA clone 265477 3' similar to SP:A60021 A60021 TROPOMYOSIN-RELATED PROTEIN, NEURONAL), and W95814 (ze07f11.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 358317 5' similar to PIR:A60021). The predicted amino acid sequence disclosed herein for BG160_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG160_1 protein demonstrated at least some identity with sequences identified as L10334 (neuroendocrine-specific protein B [Homo sapiens]), L10335 (neuroendocrine-specific protein C [Homo sapiens]). Based upon homology, BG160_1 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the BG160_1 protein sequence, centered around amino acids 84, 484, and 595 of SEQ ID NO:9.

15

Clone "BO432_4"

A polynucleotide of the present invention has been identified as clone "BO432_4". BO432_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BO432_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BO432_4 protein").

The nucleotide sequence of the 5' portion of BO432_4 as presently determined is reported in SEQ ID NO:10. An additional internal nucleotide sequence from BO432_4 as presently determined is reported in SEQ ID NO:11. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:12. Additional nucleotide sequence from the 3' portion of BO432_4, including the polyA tail, is reported in SEQ ID NO:13.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BO432_4 should be approximately 1700 bp.

The nucleotide sequence disclosed herein for BO432_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO432_4 demonstrated at least some homology with sequences

identified as AA283626 (zt15e09.s1 Soares NbHTGBC Homo sapiens cDNA clone 713224 3'), AA406486 (zv12g02.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753458 5' similar to WP F35G2.2 CE05809 E.COLI YCAC LIKE), AA570446 (nk62c12.s1 NCI_CGAP_Sch1 Homo sapiens cDNA clone IMAGE:1018102), N55855 (J3389F Homo sapiens cDNA clone J3389 5'), Q10613 (Rianodin receptor gene), T62691 (yc70d10.r1 Homo sapiens cDNA clone 86035 5'), and W90766 (zh79h04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 418327 3'). The predicted amino acid sequence disclosed herein for BO432_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BO432_4 protein demonstrated at least some identity with sequences identified as Z69637 (F35G2.2 [Caenorhabditis elegans]). Based upon homology, BO432_4 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain at the amino terminus of the BO432_4 protein sequence. The BO432_4 protein may also contain the bacterial lysR family signature, a motif found in bacterial transcriptional regulators and which is possibly indicative of a helix-turn-helix structure.

Clone "BO538_2"

A polynucleotide of the present invention has been identified as clone "BO538_2". BO538_2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BO538_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BO538_2 protein").

The nucleotide sequence of the 5' portion of BO538_2 as presently determined is reported in SEQ ID NO:14. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:15. The predicted amino acid sequence of the BO538_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:15. Additional nucleotide sequence from the 3' portion of BO538_2, including the polyA tail, is reported in SEQ ID NO:16.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BO538_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BO538_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO538_2 demonstrated at least some homology with sequences identified as AA503100 (ne44h01.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 900241),
 5 R44035 (yg21g09.s1 Homo sapiens cDNA clone 33167 3'), T21630 (Human gene signature HUMGS03066), and W64854 (me06d12.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 386711 5' similar to PIR S40989 S40989 hypothetical protein F55H2.6 - Caenorhabditis elegans). The predicted amino acid sequence disclosed herein for BO538_2 was searched against the GenPept and GeneSeq amino acid sequence
 10 databases using the BLASTX search protocol. The predicted BO538_2 protein demonstrated at least some identity with sequences identified as M60525 (nerve growth factor inducible protein [Rattus norvegicus]), R28916 (Type III procollagen), and Z27080 (F55H2.6 [Caenorhabditis elegans]). Based upon homology, BO538_2 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer
 15 program predicts two potential transmembrane domains within the BO538_2 protein sequence.

Clone "BR595_4"

A polynucleotide of the present invention has been identified as clone "BR595_4".
 20 BR595_4 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BR595_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as
 25 "BR595_4 protein").

The nucleotide sequence of the 5' portion of BR595_4 as presently determined is reported in SEQ ID NO:17. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:18. The predicted amino acid sequence of the BR595_4 protein corresponding to the foregoing nucleotide sequence is reported in
 30 SEQ ID NO:18. Additional nucleotide sequence from the 3' portion of BR595_4, including the polyA tail, is reported in SEQ ID NO:19.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BR595_4 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BR595_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BR595_4 demonstrated at least some homology with sequences identified as AA443742 (zw95b02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 784683 3'), AA600820 (np45b08.s1 NCI_CGAP_Br1.1 Homo sapiens cDNA clone IMAGE:1129239), T19410 (Human gene signature HUMGS00435), W87465 (zh67c04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 417126 3'), and Z33587 (H. sapiens partial cDNA sequence; clone HEA89P; single read). Based upon homology, BR595_4 proteins and each homologous protein or peptide may share at least some activity.

Clone "CI490_2"

A polynucleotide of the present invention has been identified as clone "CI490_2". CI490_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CI490_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CI490_2 protein").

The nucleotide sequence of CI490_2 as presently determined is reported in SEQ ID NO:20. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CI490_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:21. Amino acids 64 to 76 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 77, or are a transmembrane domain.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CI490_2 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for CI490_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI490_2 demonstrated at least some homology with sequences identified as H30751 (yo79a04.r1 Homo sapiens cDNA clone 184110 5'), H49766 (yo24f01.r1 Homo sapiens cDNA clone 178873 5' similar to SP:S19586 N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), H51158 (yo32d04.r1 Homo sapiens cDNA clone 179623 5'), R85211 (yo41d11.s1 Homo sapiens cDNA clone

180501 3' similar to SP S19586 N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), S19586 (N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), S61973 (NMDA receptor glutamate-binding subunit [rats, mRNA, 1742 nt]), T01031 (Human leucine zipper protein-kinase cDNA sequence),
 5 and W56893 (zc01g05.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321080 5' similar to PIR S19586 S19586 N-methyl-D-aspartate receptor glutamate-binding chain - rat). The predicted amino acid sequence disclosed herein for CI490_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI490_2 protein demonstrated at least some
 10 identity with sequences identified as S61973 (NMDA receptor glutamate-binding subunit [rats, Peptide, 516 aa] [Rattus sp.]) and U08020 (collagen pro-alpha-1 type I chain [Mus musculus]). Based upon homology, CI490_2 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts six potential transmembrane domains within the CI490_2 protein sequence, with the most
 15 amino-terminal transmembrane domain centered around amino acid 77 of SEQ ID NO:21.

Clone "CI522_1"

A polynucleotide of the present invention has been identified as clone "CI522_1". CI522_1 was isolated from a human adult brain cDNA library using methods which are
 20 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CI522_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CI522_1 protein").

25 The nucleotide sequence of the 5' portion of CI522_1 as presently determined is reported in SEQ ID NO:22. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:23. The predicted amino acid sequence of the CI522_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:23. Amino acids 7 to 19 are a predicted leader/signal sequence, with the
 30 predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain. Additional nucleotide sequence from the 3' portion of CI522_1, including the polyA tail, is reported in SEQ ID NO:24.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CI522_1 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for CI522_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI522_1 demonstrated at least some homology with sequences identified as AA028557 (mi18g05.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone
5 463928 5'), H32238 (EST107136 Rattus sp. cDNA 5' end), T33525 (EST58140 Homo sapiens cDNA 5' end similar to None), U66468 (Human cell growth regulator CGR11 mRNA, complete cds), and X00525 (Mouse 28S ribosomal RNA). The predicted amino acid sequence disclosed herein for CI522_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI522_1
10 protein demonstrated at least some identity with sequences identified as U66468 (cell growth regulator CGR11 [Homo sapiens]). Based upon homology, CI522_1 proteins and each homologous protein or peptide may share at least some activity.

Clone "CN238_1"

15 A polynucleotide of the present invention has been identified as clone "CN238_1". CN238_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CN238_1 is a full-length
20 clone, including the entire coding sequence of a secreted protein (also referred to herein as "CN238_1 protein").

The nucleotide sequence of CN238_1 as presently determined is reported in SEQ ID NO:25. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CN238_1 protein corresponding to the foregoing
25 nucleotide sequence is reported in SEQ ID NO:26.

The nucleotide sequence disclosed herein for CN238_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CN238_1 demonstrated at least some homology with sequences
30 identified as AA044097 (zk51b02.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486315 5'), AA044287 (zk51b02.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486315 3'), AA045440 (zk67c03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487876 3'), AA143007 (zl48f01.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 505177 5'), D51196 (Human fetal brain cDNA 3'-end

GEN-016G05), D60310 (Human fetal brain cDNA 3'-end GEN-098A09), N69344 (yz43e04.s1 Homo sapiens cDNA clone 285822 3' similar to gb:K00558 TUBULIN ALPHA-1 CHAIN (HUMAN)), W22250 (64B8 Human retina cDNA Tsp509I-cleaved sublibrary Homo), and X01703 (Human gene for alpha-tubulin (b alpha 1)). The predicted amino acid sequence disclosed herein for CN238_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CN238_1 protein demonstrated at least some identity with sequences identified as K00557 (alpha-tubulin [Homo sapiens]) and U51583 (zinc finger homeodomain enhancer-binding protein-1 [Rattus norvegicus]). Based upon homology, CN238_1 proteins and each homologous protein or peptide may share at least some activity.

Clone "CO390_1"

A polynucleotide of the present invention has been identified as clone "CO390_1". CO390_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CO390_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CO390_1 protein").

The nucleotide sequence of CO390_1 as presently determined is reported in SEQ ID NO:27. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CO390_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CO390_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for CO390_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO390_1 demonstrated at least some homology with sequences identified as H84353 (yv85a11.r1 Homo sapiens cDNA clone 249500 5'), L35532 (Pan troglodytes Alu repeat region), N80616 (Genomic clone encoding SAP(Phe)), R53922 (yi03h10.s1 Homo sapiens cDNA clone 138211 3' similar to contains Alu repetitive element; contains TAR1 repetitive element), X75335 (H.sapiens Alu insertion in COL3A1 gene), X95882 (R.norvegicus mRNA for ATP ligand gated ion channel), and Y09561 (H.sapiens mRNA for P2X7 receptor). The predicted amino acid sequence disclosed

herein for CO390_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CO390_1 protein demonstrated at least some identity with sequences identified as U45448 (P2x1 receptor [Homo sapiens]), W04216 (Rat superior cervical ganglion p2x receptor), X83688 (ATP receptor [Homo sapiens]), X95882 (P2X7 gene product [Rattus norvegicus]), and Y09561 (ATP receptor [Homo sapiens]). Based upon homology, CO390_1 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the CO390_1 protein sequence, centered around amino acid 249 of SEQ ID NO:28. The nucleotide sequence of CO390_1 may contain an Alu repetitive element.

Deposit of Clones

Clones AR415_4, AS63_29, BG160_1, BO432_4, BO538_2, BR595_4, CI490_2, CI522_1, CN238_1, CO390_1, and AY304_1 (an additional isolate of clone AY304_14) were deposited on October 25, 1996 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98232, from which each clone comprising a particular polynucleotide is obtainable. Clone AY304_14 was deposited on October 23, 1997 with the American Type Culture Collection as an original deposit under the Budapest Treaty and was given the accession number ATCC xxxxx. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b).

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site

and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite
5 deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below,
10 and should be most reliable in isolating the clone of interest.

<u>Clone</u>	<u>Probe Sequence</u>
AR415_4	SEQ ID NO:29
AS63_29	SEQ ID NO:30
15 AY304_14	SEQ ID NO:31
BG160_1	SEQ ID NO:32
BO432_4	SEQ ID NO:33
BO538_2	SEQ ID NO:34
BR595_4	SEQ ID NO:35
20 CI490_2	SEQ ID NO:36
CI522_1	SEQ ID NO:37
CN238_1	SEQ ID NO:38
CO390_1	SEQ ID NO:39

25 In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

30 The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;

- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ -³²P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmol.

- 10 The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 µl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 µg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

- 20 Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

- The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R.S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the cDNA sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which the cDNA sequences are derived and any contiguous regions of the genome necessary for the regulated expression of such genes, including but not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials.

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and
5 transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence
10 identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more
15 (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making
20 suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded
25 by the polynucleotides .

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most
30 preferably, highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

	Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [†]	Hybridization Temperature and Buffer [†]	Wash Temperature and Buffer [†]
5	A	DNA:DNA	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	DNA:DNA	<50	T _B *; 1xSSC	T _B *; 1xSSC
	C	DNA:RNA	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	DNA:RNA	<50	T _D *; 1xSSC	T _D *; 1xSSC
	E	RNA:RNA	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	RNA:RNA	<50	T _F *; 1xSSC	T _F *; 1xSSC
10	G	DNA:DNA	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	DNA:DNA	<50	T _H *; 4xSSC	T _H *; 4xSSC
	I	DNA:RNA	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	DNA:RNA	<50	T _J *; 4xSSC	T _J *; 4xSSC
	K	RNA:RNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	RNA:RNA	<50	T _L *; 2xSSC	T _L *; 2xSSC
15	M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	DNA:DNA	<50	T _N *; 6xSSC	T _N *; 6xSSC
	O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	DNA:RNA	<50	T _P *; 6xSSC	T _P *; 6xSSC
	Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	20	R	RNA:RNA	<50	T _R *; 4xSSC

[‡] The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[†] SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

*T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,
5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or
10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an
15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably
20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the
25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, *e.g.*, silica gel having pendant

methyle or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance
5 with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

10 The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith,
15 including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally
20 provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another
25 amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be
30 expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which

the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays

for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured
5 by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter
10 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node
15 cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

20 Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature*
25 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols*
30 *in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for

example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or

tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosis in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of

viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.

Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, *Immunologic studies in Humans*); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnoli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

25 Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

30 Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter

7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent

myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of
5 hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or
10 *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et
20 al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of*
25 *Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359,
30 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland,

H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol .pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

5 A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

10 A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De*
15 *novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

20 A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue
25 destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

30 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and
35 other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of

congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce
5 differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in
10 the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve
15 tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present
20 invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of
25 non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac)
30 and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting
5 differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described
10 in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year
15 Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related
20 activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals
25 and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example,
30 United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

5

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.

10 Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses
15 against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population
20 of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent
25 chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene
30 Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. *J. Clin. Invest.* 95:1370-1376, 1995; Lind et al. *APMIS* 103:140-146, 1995; Muller et al. *Eur. J. Immunol.* 25: 1744-1748; Gruber et al. *J. of Immunol.* 152:5860-5867, 1994; Johnston et al. *J. of Immunol.* 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 15 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

30 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and

Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 5 1995.

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in 10 the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat 15 inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting 20 from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major 25 roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

30 The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the

first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

5 E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to
10 their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention
15 encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue
20 in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and
25 polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the
30 cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used

to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides
5 encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

10 Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or
15 tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

20 Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height,
25 weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein,
30 carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic

- lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen
- 5 in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

- 10 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term
- 15 "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,
- 20 IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention,
- 25 or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
- 30 A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be

administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred

pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The
5 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.
10 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not
15 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μ g to about 100 mg (preferably about 0.1ng to about 10 mg, more preferably about 0.1 μ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the
20 present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous
25 therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the
30 carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal

antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting
5 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When
10 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also
15 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the
20 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular
25 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins
30 or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-

aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.

- 5 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, 10 ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 15 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

- 20 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

- 25 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering 30 various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in

the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline

5 labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without

10 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

15 Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Jacobs, Kenneth
McCoy, John M.
LaVallie, Edward R.
Racie, Lisa A.
Merberg, David
Treacy, Maurice
Spaulding, Vikki
Agostino, Michael
- (ii) TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
ENCODING THEM
- (iii) NUMBER OF SEQUENCES: 39
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Genetics Institute, Inc.
 - (B) STREET: 87 CambridgePark Drive
 - (C) CITY: Cambridge
 - (D) STATE: MA
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Sprunger, Suzanne A.
 - (B) REGISTRATION NUMBER: 41,323
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 498-8284
 - (B) TELEFAX: (617) 876-5851

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1605 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACGCTGACCA TCACAGGCAC ACAGAGGCAC ATCCACCTCA CATCCACCTC ATACTTGTGT	60
ACTCTCAGGG TTCAGTCTTT CATCCTATCC CTCTCTGATC TGTGCCTCCC AATACCTTCC	120
AAGATGTTTA CAGAGACCCT TCTCCCTGTG CAGTTAGGAG TGTAAGGCAA GAGAGCCCCT	180
ACTTCATGGG GCAGATCAAG AGCTGAGACC AAAGATGGTC TATGTTGCTG ACCTTGTCTT	240
GTCCTCCTGC TGTCTTAAAC TATGATCCCT GCTGCGGTCA CTGAAGCCTT TCCCTGTGAG	300
CAGTGGTGTG TGAGAGCCAG GCGTCCCTCT GCCTGCCAC TCAGTGGCAA CACCCGGGAG	360
CTGTTTGTG CTTTGTGGAG CCTCAGCAGT TCCCTCTTTC AGAACTCACT GCCAAGAGCC	420
CTGAACAGGA GCCACCATGC AGTGCTTCAG CTTCAATTAAG ACCATGATGA TCCTCTTCAA	480
TTTGCTCATC TTTCTGTGTG GTGCAGCCCT GTTGGCAGTG GGCATCTGGG TGTCAATCGA	540
TGGGGCATCC TTTCTGAAGA TCTTCGGGCC ACTGTCGTCC AGTGCCATGC AGTTTGTCAA	600
CGTGGGCTAC TTCCTCATCG CAGCCGGCGT TGTGGTCTTT GCTCTTGGTT TCCTGGGCTG	660
CTATGGTGCT AAGACTGAGA GCAAGTGTGC CCTCGTGACG TTCTTCTTCA TCCTCCTCCT	720
CATCTTCATT GCTGAGGTTG CAGCTGCTGT GGTGCGCTTG GTGTACACCA CAATGGCTGA	780
GCACTTCCTG ACGTTGCTGG TAGTGCCTGC CATCAAGAAA GATTATGGTT CCCAGGAAGA	840
CTTCACTCAA GTGTGGAACA CCACCATGAA AGGGCTCAAG TGCTGTGGCT TCACCAACTA	900
TACGGATTTT GAGGACTCAC CCTACTTCAA AGAGAACAGT GCCTTTCCCC CATTCGTGTG	960
CAATGACAAC GTCACCAACA CAGCCAATGA AACCTGCACC AAGCAAAAGG CTCACGACCA	1020
AAAAGTAGAG GGTGCTTCA ATCAGCTTTT GTATGACATC CGAACTAATG CAGTCACCGT	1080
GGGTGGTGTG GCAGCTGGA TTGGGGGCCT CGAGCTGGCT GCCATGATTG TGTCCATGTA	1140
TCTGTACTGC AATCTACAAT AAGTCCACTT CTGCCTCTGC CACTACTGCT GCCACATGGG	1200
AACTGTGAAG AGGCACCCTG GCAAGCAGCA GTGATTGGGG GAGGGGACAG GATCTAACAA	1260
TGTCACTTGG GCCAGAATGG ACCTGCCCTT TCTGCTCCAG ACTTGGGGGT AGATAGGGAC	1320
CACTCCTTTT AGGCGATGCC TGACTTTCTT TCCATTGGTG GGTGGATGGG TGGGGGGCAT	1380
TCCAGAGCCT CTAAGGTAGC CAGTTCTGTT GCCCATTTCC CCAGTCTATT AAACCTTGA	1440
TATGCCCCCT AGGCCTAGTG GTGATCCAG TGCTCTACTG GGGGATGAGA GAAAGGCATT	1500
TTATAGCCTG GGCATAAGTG AAATCAGCAG AGCCTCTGGG TGGATGTGTA GAAGGCACTT	1560

CAAAATGCAT AAACCTGTTA CAATGTTGAA AAAAAAAAAA AAAAA

1605

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 241 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu
1 5 10 15

Leu Ile Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly Ile Trp Val
20 25 30

Ser Ile Asp Gly Ala Ser Phe Leu Lys Ile Phe Gly Pro Leu Ser Ser
35 40 45

Ser Ala Met Gln Phe Val Asn Val Gly Tyr Phe Leu Ile Ala Ala Gly
50 55 60

Val Val Val Phe Ala Leu Gly Phe Leu Gly Cys Tyr Gly Ala Lys Thr
65 70 75 80

Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile
85 90 95

Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr
100 105 110

Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys
115 120 125

Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met
130 135 140

Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp
145 150 155 160

Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn
165 170 175

Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala
180 185 190

His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile
195 200 205

Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly
 210 215 220

Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu
 225 230 235 240

Gln

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 377 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAACCTCGTG GTCACCGCAC CGGGGCTGAT CAAGGGTGAC GCCTGCTTCA CATCTCTAAT 60

GAACACCCCTC ATGACGTCGC TACCAGCACT AGTGCAGCAA CAGGGAAGGC TGCTTCTGGC 120

TGCTAATGTG GCCACCCTGG GGCTCCTCAT GGCCCGGCTC CTTAGCACCT CTCCAGCTCT 180

TCAGGGAACA CCAGCATCCC GAGGGTTCTT CGCAGCTGCC ATCCTCTTCC TATCACAGTC 240

CCACGTGGCG CGGGCCACCC CGGGCTCAGA CCAGGCAGTG CTAGCCCTGT CCCCTGAGTA 300

TGAGGGCATC TGGGCCGACC TGCAGGAGCT CTGGTTCCTG GGCATNCAAG CCTTACCAGG 360

CTGTGTGCCT CTGCTGC 377

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 106 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Asn Thr Leu Met Thr Ser Leu Pro Ala Leu Val Gln Gln Gln Gly
 1 5 10 15

Arg Leu Leu Leu Ala Ala Asn Val Ala Thr Leu Gly Leu Leu Met Ala
 20 25 30

Arg Leu Leu Ser Thr Ser Pro Ala Leu Gln Gly Thr Pro Ala Ser Arg
 35 40 45

Gly Phe Phe Ala Ala Ala Ile Leu Phe Leu Ser Gln Ser His Val Ala
 50 55 60

Arg Ala Thr Pro Gly Ser Asp Gln Ala Val Leu Ala Leu Ser Pro Glu
 65 70 75 80

Tyr Glu Gly Ile Trp Ala Asp Leu Gln Glu Leu Trp Phe Leu Gly Xaa
 85 90 95

Gln Ala Phe Thr Gly Cys Val Pro Leu Leu
 100 105

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 245 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TANGACTCCT CTCTGCNGAG ACGCGACTGG CGGNTCCAGC AGGGANTACC TTTTTTATAA 60

ACCCNGGGGG NCCACACACA CACACACACA CACACACACA CACACACACA CACACACACA 120

CATTTTGTGAT CCCTTGCTTC CNTCCCCCAG TGC GTTCTGT GATCGCCAAG TTCAAAGCTG 180

TGCACATGTG GAACTCAAT AAATGTTTAT TGGNGACAAA AAAAAAAAAA AAAAAAAAAA 240

AAAAA 245

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2384 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCAAAACATG CTCAAAAGTA GAACATTTTG TTTCAATATT AGGAAAGTGC TTTGAATCCC	60
CTTGGACGAC AAAAGCGTTG TCTGAGACAG CATGCGAAGA CTCAGAGGAA AACAAGCAGA	120
GAATAACAGG TGCCCAGACT CTACCAAAGC ATGTTTCTAC CAGCAGTGAT GAAGGGAGCC	180
CCAGTGCCAG TACACCAATG ATCAATAAAA CTGGCTTTAA ATTTTCAGCT GAGAAGCCTG	240
TGATTGAAGT TCCCAGCATG ACAATCCTGG ATAAAAAGGA TGGAGAGCAG GCCAAAGCCC	300
TGTTTGAGAA AGTGAGGAAG TTCCGTGCCC ATGTGGAAGA TAGTGACTTG ATCTATAAAC	360
TCTATGTGGT CCAAACAGTT ATCAAAACAG CCAAGTTCAT TTTTATTCTC TGCTATACAG	420
CGAACTTTGT CAACGCAATC AGCTTTGAAC ACGTCTGCAA GCCCAAAGTT GAGCATCTGA	480
TTGGTTATGA GGTATTTGAG TGCACCCACA ATATGGCTTA CATGTTGAAA AAGCTTCTCA	540
TCAGTTACAT ATCCATTATT TGTGTTTATG GCTTTATCTG CCTCTACACT CTCTTCTGGT	600
TATTCAGGAT ACCTTTGAAG GAATATTCTT TCGAAAAAGT CAGAGAAGAG AGCAGTTTTA	660
GTGACATTCC AGATGTCAAA AACGATTTTG CGTTCCTTCT TCACATGGTA GACCAGTATG	720
ACCAGCTATA TTCCAAGCGT TTTGGTGTGT TCTTGTCAGA AGTTAGTGAA AATAAACTTA	780
GGGAAATTAG TTTGAACCAT GAGTGGACAT TTGAAAAACT CAGGCAGCAC ATTTACGCA	840
ACGCCCAGGA CAAGCAGGAG TTGCATCTGT TCATGCTGTC GGGGGTGCCC GATGCTGTCT	900
TTGACCTCAC AGACCTGGAT GTGCTAAAGC TTGAACTAAT TCCAGAAGCT AAAATTCCTG	960
CTAAGATTTC TCAAATGACT AACCTCCAAG AGCTCCACCT CTGCCACTGC CCTGCAAAAG	1020
TTGAACAGAC TGCTTTTAGC TTTCTTCGCG ATCACTTGAG ATGCC TTCAC GTGAAGTTCA	1080
CTGATGTGGC TGAAATTCCT GCCTGGGTGT ATTTGCTCAA AAACCTTCGA GAGTTGTACT	1140
TAATAGGCAA TTTGAACTCT GAAAACAATA AGATGATAGG ACTTGAATCT CTCCGAGAGT	1200
TGCGGCACCT TAAGATTCTC CACGTGAAGA GCAATTTGAC CAAAGTTCCC TCCAACATTA	1260
CAGATGTGGC TCCACATCTT ACAAAGTTAG TCATTCATAA TGACGGCACT AAACCTTTGG	1320
TACTGAACAG CCTTAAGAAA ATGATGAATG TCGCTGAGCT GGAACCTCAG AACTGTGAGC	1380
TAGAGAGAAT CCCACATGCT ATTTTCAGCC TCTCTAATTT ACAGGAAC TG GATTAAAGT	1440
CCAATAACAT TCGCACAATT GAGGAAATCA TCAGTTTCCA GCATTAAAA CGACTGACTT	1500
GTTTAAATTT ATGGCATAAC AAAATTGTTA CTATTCCTCC CTCTATTACC CATGTCAAAA	1560
ACTTGGAGTC ACTTTATTTT TCTAACAACA AGCTCGAATC CTTACCAGTG GCAGTATTTA	1620

```

GTTTACAGAA ACTCAGATGC TTAGATGTGA GCTACAACAA CATTTC AATG ATTCCAATAG 1680
AAATAGGATT GCTTCAGAAC CTGCAGCATT TGCATATCAC TGGGAACAAA GTGGACATTC 1740
TGCCAAAACA ATTGTTTAAA TGCATAAAGT TGAGGACTTT GAATCTGGGA CAGAACTGCA 1800
TCACCTCACT CCCAGAGAAA GTTGGTCAGC TCTCCCAGCT CACTCAGCTG GAGCTGAAGG 1860
GGAAGTCTT GGACCGCCTG CCAGCCCAGC TGGGCCAGTG TCGGATGCTC AAGAAAAGCG 1920
GGCTTGTGT GGAAGATCAC CTTTTTGATA CCCTGCCACT CGAAGTCAAA GAGGCATTGA 1980
ATCAAGACAT AAATATTCCC TTTGCAAATG GGATTTAMAC TAAGATAATA TATGCACAGT 2040
GATGTGCAGG AACAACTTCC TAGATTGCAA GTGCTCACGT ACAAGTTATT ACAAGATAAT 2100
GCATTTTAGG AGTAGATACA TCTTTTAAAA TAAAACAGAG AGGATGCATA GAAGGCTGAT 2160
AGAAGACATA ACTGAATGTT CAATGTTTGT AGGGTTTTAA GTCATTCATT TCCAAATCAT 2220
TTTTTTTTTT CTTTGGGGA AAGGGAAGGA AAAATTATAA TCACTAATCT TGGTTCTTTT 2280
TAAATTGTTT GTAAGTTGGA TGCTGCCGCT ACTGAATGTT TACAAATTGC TTGCCTGCTA 2340
AAGTAAATGA TTAAATTGAC ATTTTCTTAC TATAAAAAAA AAAA 2384

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 614 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Met Ile Asn Lys Thr Gly Phe Lys Phe Ser Ala Glu Lys Pro Val Ile
1           5           10           15

Glu Val Pro Ser Met Thr Ile Leu Asp Lys Lys Asp Gly Glu Gln Ala
20           25           30

Lys Ala Leu Phe Glu Lys Val Arg Lys Phe Arg Ala His Val Glu Asp
35           40           45

Ser Asp Leu Ile Tyr Lys Leu Tyr Val Val Gln Thr Val Ile Lys Thr
50           55           60

Ala Lys Phe Ile Phe Ile Leu Cys Tyr Thr Ala Asn Phe Val Asn Ala
65           70           75           80

```

Ile Ser Phe Glu His Val Cys Lys Pro Lys Val Glu His Leu Ile Gly
 85 90 95
 Tyr Glu Val Phe Glu Cys Thr His Asn Met Ala Tyr Met Leu Lys Lys
 100 105 110
 Leu Leu Ile Ser Tyr Ile Ser Ile Ile Cys Val Tyr Gly Phe Ile Cys
 115 120 125
 Leu Tyr Thr Leu Phe Trp Leu Phe Arg Ile Pro Leu Lys Glu Tyr Ser
 130 135 140
 Phe Glu Lys Val Arg Glu Glu Ser Ser Phe Ser Asp Ile Pro Asp Val
 145 150 155 160
 Lys Asn Asp Phe Ala Phe Leu Leu His Met Val Asp Gln Tyr Asp Gln
 165 170 175
 Leu Tyr Ser Lys Arg Phe Gly Val Phe Leu Ser Glu Val Ser Glu Asn
 180 185 190
 Lys Leu Arg Glu Ile Ser Leu Asn His Glu Trp Thr Phe Glu Lys Leu
 195 200 205
 Arg Gln His Ile Ser Arg Asn Ala Gln Asp Lys Gln Glu Leu His Leu
 210 215 220
 Phe Met Leu Ser Gly Val Pro Asp Ala Val Phe Asp Leu Thr Asp Leu
 225 230 235 240
 Asp Val Leu Lys Leu Glu Leu Ile Pro Glu Ala Lys Ile Pro Ala Lys
 245 250 255
 Ile Ser Gln Met Thr Asn Leu Gln Glu Leu His Leu Cys His Cys Pro
 260 265 270
 Ala Lys Val Glu Gln Thr Ala Phe Ser Phe Leu Arg Asp His Leu Arg
 275 280 285
 Cys Leu His Val Lys Phe Thr Asp Val Ala Glu Ile Pro Ala Trp Val
 290 295 300
 Tyr Leu Leu Lys Asn Leu Arg Glu Leu Tyr Leu Ile Gly Asn Leu Asn
 305 310 315 320
 Ser Glu Asn Asn Lys Met Ile Gly Leu Glu Ser Leu Arg Glu Leu Arg
 325 330 335
 His Leu Lys Ile Leu His Val Lys Ser Asn Leu Thr Lys Val Pro Ser
 340 345 350
 Asn Ile Thr Asp Val Ala Pro His Leu Thr Lys Leu Val Ile His Asn
 355 360 365
 Asp Gly Thr Lys Leu Leu Val Leu Asn Ser Leu Lys Lys Met Met Asn
 370 375 380

```

Val Ala Glu Leu Glu Leu Gln Asn Cys Glu Leu Glu Arg Ile Pro His
385                      390                      395                      400

Ala Ile Phe Ser Leu Ser Asn Leu Gln Glu Leu Asp Leu Lys Ser Asn
                      405                      410                      415

Asn Ile Arg Thr Ile Glu Glu Ile Ile Ser Phe Gln His Leu Lys Arg
                      420                      425                      430

Leu Thr Cys Leu Lys Leu Trp His Asn Lys Ile Val Thr Ile Pro Pro
                      435                      440                      445

Ser Ile Thr His Val Lys Asn Leu Glu Ser Leu Tyr Phe Ser Asn Asn
                      450                      455                      460

Lys Leu Glu Ser Leu Pro Val Ala Val Phe Ser Leu Gln Lys Leu Arg
465                      470                      475                      480

Cys Leu Asp Val Ser Tyr Asn Asn Ile Ser Met Ile Pro Ile Glu Ile
                      485                      490                      495

Gly Leu Leu Gln Asn Leu Gln His Leu His Ile Thr Gly Asn Lys Val
                      500                      505                      510

Asp Ile Leu Pro Lys Gln Leu Phe Lys Cys Ile Lys Leu Arg Thr Leu
                      515                      520                      525

Asn Leu Gly Gln Asn Cys Ile Thr Ser Leu Pro Glu Lys Val Gly Gln
530                      535                      540

Leu Ser Gln Leu Thr Gln Leu Glu Leu Lys Gly Asn Cys Leu Asp Arg
545                      550                      555                      560

Leu Pro Ala Gln Leu Gly Gln Cys Arg Met Leu Lys Lys Ser Gly Leu
                      565                      570                      575

Val Val Glu Asp His Leu Phe Asp Thr Leu Pro Leu Glu Val Lys Glu
                      580                      585                      590

Ala Leu Asn Gln Asp Ile Asn Ile Pro Phe Ala Asn Gly Ile Xaa Thr
595                      600                      605

Lys Ile Ile Tyr Ala Gln
610

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2386 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCAAAACATC AAACCTTTT CTGTAGCAG CACAGGATTC TGAGACAGAT TATGTCACAA	60
CAGATAATTT AACAAAGGTG ACTGAGGAAG TCGTGGCAAA CATGCCTGAA GGCCTGACTC	120
CAGATTTAGT ACAGGAAGCA TGTGAAAGTG AATTGAATGA AGTTACTGGT ACAAAGATTG	180
CTTATGAAAC AAAAATGGAC TTGGTTCAAA CATCAGAAGT TATGCAAGAG TCACTCTATC	240
CTGCAGCACA GCTTTGCCCA TCATTGGAAG AGTCAGAAGC TACTCCTTCA CCAGTTTTCG	300
CTGACATTGT TATGGAAGCA CCATTGAATT CTGCAGTTCC TAGTGCTGGT GCTTCCGTGA	360
TACAGCCCAG CTCATCACCA TTAGAAGCTT CTTCAAGTAA TTATGAAAGC ATAAAACATG	420
AGCCTGAAAA CCCCCACCA TATGAAGAGG CCATGAGTGT ATCACTAAAA AAAGTATCAG	480
GAATAAGGA AGAAATTAAA GAGCCTGAAA ATATTAATGC AGCTCTTCAA GAAACAGAAG	540
CTCCTTATAT ATCTATTGCA TGTGATTTAA TTAAAGAAAC AAAGCTTTCT GCTGAACCAG	600
CTCCGGATTT CTCTGATTAT TCAGAAATGG CAAAAGTTGA ACAGCCAGTG CCTGATCATT	660
CTGAGCTAGT TGAAGATTCC TCACCTGATT CTGAACCAGT TGAATTATTT AGTGATGATT	720
CAATACCTGA CGTTCCACAA AAACAAGATG AAAGTGTGAT GCTTGTGAAA GAAAGTCTCA	780
CTGAGACTTC ATTTGAGTCA ATGATAGAAT ATGAAAATAA GGAAAACTC AGTGCTTTGC	840
CACCTGAGGG AGGAAAGCCA TATTTGGAAT CTTTAAAGCT CAGTTTAGAT AACACAAAAG	900
ATACCCTGTT ACCTGATGAA GTTTCAACAT TGAGCAAAAA GGAGAAAATT CCTTTGCAGA	960
TGGAGGAGCT CAGTACTGCA GTTTATTCAA ATGATGACTT ATTTATTTCT AAGGAAGCAC	1020
AGATAAGAGA AACTGAAACG TTTTCAGATT CATCTCCAAT TGAAATTATA GATGAGTTCC	1080
CTACATTGAT CAGTTCTAAA ACTGATTCAT TTTCTAAATT AGCCAGGGAA TATACTGACC	1140
TAGAAGTATC CCACAAAAGT GAAATTGCTA ATGCCCCGGA TGGAGCTGGG TCATTGCCTT	1200
GCACAGAATT GCCCCATGAC CTTTCTTTGA AGAACATACA ACCCAAAGTT GAAGAGAAAA	1260
TCAGTTTCTC AGATGACTTT TCTAAAAATG GGTCTGCTAC ATCAAAGGTG CTCTTATTGC	1320
CTCCAGATGT TTCTGCTTTG GCCACTCAAG CAGAGATAGA GAGCATAGTT AAACCCAAAG	1380
TTCTTGTGAA AGAAGCTGAG AAAAACTTC CTTCCGATAC AGAAAAAGAG GACAGATCAC	1440
CATCTGCTAT ATTTTCAGCA GAGCTGAGTA AAAGTTTCAAG TGTGACCTC CTGTACTGGA	1500
GAGACATTAA GAAGACTGGA GTGGTGTGTT GTGCCAGCCT ATTCCTGCTG CTTTCATTGA	1560
CAGTATTCAG CATTGTGAGC GTAACAGCCT ACATTGCCTT GGCCCTGCTC TCTGTGACCA	1620


```

TCAGCTTTAG GATATACAAG GGTGTGATCC AAGCTATCCA GAAATCAGAT GAAGGCCACC   1680
CATTACAGGA AGTTGCTATA TCTGAGGAGT TGGTTCAGAA GTACAGTAAT TCTGCTCTTG   1740
GTCATGTGAA CTGCACGATA AAGGAACTCA GCGCCTCTT CTTAGTTGAT GATTTAGTTG   1800
ATTCTCTGAA GTTTGCAGTG TTGATGTGGG TATTTACCTA TGTGGTGCC TTGTTTAATG   1860
GTCTGACACT ACTGATTTTG GCTCTCATTT CACTCTTCAG TGTTCCTGTT ATTTATGAAC   1920
GGCATCAGGC ACAGATAGAT CATTATCTAG GACTTGCAAA TAAGAATGTT AAAGATGCTA   1980
TGGCTAAAAT CCAAGCAAAA ATCCCTGGAT TGAAGCGCAA AGCTGAATGA AAACGCCCAA   2040
AATAATTAGT AGGAGTTCAT CTTTAAAGGG GATATTCATT TGATTATACG GGGGAGGGTC   2100
AGGAAGAAGC GAACCTGAC GTTGCACTGC AGTTTCACAG ATCGTTGTGA GATCTTTATT   2160
TTTAGCCATG CACTGTTGTG AGGAAAAATT ACCTGTCTTG ACTGCCATGT GTTCATCATC   2220
TTAAGTATTG TAAGCTGCTA TGTATGGATT TAAACCGTAA TCATATCTTT TTCCTATCTG   2280
AGGCACTGGT GGAATAAAAA ACCTGTATAT TTTACTTTGT TGCAGATAGT CTTGCCGCAT   2340
CTTGGCAAGT TGCAGAGATG GTGGAGCTAG AAAAAAAAAA AAAAAA   2386

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 642 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Met  Pro  Glu  Gly  Leu  Thr  Pro  Asp  Leu  Val  Gln  Glu  Ala  Cys  Glu  Ser
1              5              10              15

Glu  Leu  Asn  Glu  Val  Thr  Gly  Thr  Lys  Ile  Ala  Tyr  Glu  Thr  Lys  Met
                20              25              30

Asp  Leu  Val  Gln  Thr  Ser  Glu  Val  Met  Gln  Glu  Ser  Leu  Tyr  Pro  Ala
                35              40              45

Ala  Gln  Leu  Cys  Pro  Ser  Phe  Glu  Glu  Ser  Glu  Ala  Thr  Pro  Ser  Pro
50              55              60

Val  Leu  Pro  Asp  Ile  Val  Met  Glu  Ala  Pro  Leu  Asn  Ser  Ala  Val  Pro
65              70              75              80

```

Ser Ala Gly Ala Ser Val Ile Gln Pro Ser Ser Ser Pro Leu Glu Ala
 85 90 95
 Ser Ser Val Asn Tyr Glu Ser Ile Lys His Glu Pro Glu Asn Pro Pro
 100 105 110
 Pro Tyr Glu Glu Ala Met Ser Val Ser Leu Lys Lys Val Ser Gly Ile
 115 120 125
 Lys Glu Glu Ile Lys Glu Pro Glu Asn Ile Asn Ala Ala Leu Gln Glu
 130 135 140
 Thr Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp Leu Ile Lys Glu Thr
 145 150 155 160
 Lys Leu Ser Ala Glu Pro Ala Pro Asp Phe Ser Asp Tyr Ser Glu Met
 165 170 175
 Ala Lys Val Glu Gln Pro Val Pro Asp His Ser Glu Leu Val Glu Asp
 180 185 190
 Ser Ser Pro Asp Ser Glu Pro Val Asp Leu Phe Ser Asp Asp Ser Ile
 195 200 205
 Pro Asp Val Pro Gln Lys Gln Asp Glu Thr Val Met Leu Val Lys Glu
 210 215 220
 Ser Leu Thr Glu Thr Ser Phe Glu Ser Met Ile Glu Tyr Glu Asn Lys
 225 230 235 240
 Glu Lys Leu Ser Ala Leu Pro Pro Glu Gly Gly Lys Pro Tyr Leu Glu
 245 250 255
 Ser Phe Lys Leu Ser Leu Asp Asn Thr Lys Asp Thr Leu Leu Pro Asp
 260 265 270
 Glu Val Ser Thr Leu Ser Lys Lys Glu Lys Ile Pro Leu Gln Met Glu
 275 280 285
 Glu Leu Ser Thr Ala Val Tyr Ser Asn Asp Asp Leu Phe Ile Ser Lys
 290 295 300
 Glu Ala Gln Ile Arg Glu Thr Glu Thr Phe Ser Asp Ser Ser Pro Ile
 305 310 315 320
 Glu Ile Ile Asp Glu Phe Pro Thr Leu Ile Ser Ser Lys Thr Asp Ser
 325 330 335
 Phe Ser Lys Leu Ala Arg Glu Tyr Thr Asp Leu Glu Val Ser His Lys
 340 345 350
 Ser Glu Ile Ala Asn Ala Pro Asp Gly Ala Gly Ser Leu Pro Cys Thr
 355 360 365
 Glu Leu Pro His Asp Leu Ser Leu Lys Asn Ile Gln Pro Lys Val Glu
 370 375 380

Glu Lys Ile Ser Phe Ser Asp Asp Phe Ser Lys Asn Gly Ser Ala Thr
 385 390 395 400
 Ser Lys Val Leu Leu Leu Pro Pro Asp Val Ser Ala Leu Ala Thr Gln
 405 410 415
 Ala Glu Ile Glu Ser Ile Val Lys Pro Lys Val Leu Val Lys Glu Ala
 420 425 430
 Glu Lys Lys Leu Pro Ser Asp Thr Glu Lys Glu Asp Arg Ser Pro Ser
 435 440 445
 Ala Ile Phe Ser Ala Glu Leu Ser Lys Thr Ser Val Val Asp Leu Leu
 450 455 460
 Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val Val Phe Gly Ala Ser Leu
 465 470 475 480
 Phe Leu Leu Leu Ser Leu Thr Val Phe Ser Ile Val Ser Val Thr Ala
 485 490 495
 Tyr Ile Ala Leu Ala Leu Leu Ser Val Thr Ile Ser Phe Arg Ile Tyr
 500 505 510
 Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro Phe
 515 520 525
 Arg Glu Val Ala Ile Ser Glu Glu Leu Val Gln Lys Tyr Ser Asn Ser
 530 535 540
 Ala Leu Gly His Val Asn Cys Thr Ile Lys Glu Leu Arg Arg Leu Phe
 545 550 555 560
 Leu Val Asp Asp Leu Val Asp Ser Leu Lys Phe Ala Val Leu Met Trp
 565 570 575
 Val Phe Thr Tyr Val Gly Ala Leu Phe Asn Gly Leu Thr Leu Leu Ile
 580 585 590
 Leu Ala Leu Ile Ser Leu Phe Ser Val Pro Val Ile Tyr Glu Arg His
 595 600 605
 Gln Ala Gln Ile Asp His Tyr Leu Gly Leu Ala Asn Lys Asn Val Lys
 610 615 620
 Asp Ala Met Ala Lys Ile Gln Ala Lys Ile Pro Gly Leu Lys Arg Lys
 625 630 635 640
 Ala Glu

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 344 base pairs

(B) TYPE: nucleic acid

- (C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

GGCGGCTGCG GANCCGGCGG TCCTTGCGCT CCCCAACANC GGCGCCGGGG GCGCGGGGGC   60
GCCGTCGGGC ACAGTCCCGG TGCTCTTCTG TTTCTCAGTC TTCGCGCGAC CCTCGTCGGT   120
GCCACACGGG GCGGGCTACA AGCTGCTCAT CCAGAAGTTC CTCAGCCTGT ACGGCGACCA   180
GATCNACATG CACCGCAAAT TCGTGGTGCA GCTGTTGCGC GAGGAGTGGG GCCAGTACGT   240
GGACTTGCCC AAGGGCTTCN CGGTGAGCGA GCGCTGCAAG GTGCGCCTCG TGCCGCTGCA   300
TATCCAGCTC ACTACCCTGG GAAATCTTAC ACCTTCAAGC ACTG                       344

```

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 631 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

ACATGATTCA GAGTCCTGTG GGTAAATTCA TATGCAATA TCTTATTCCA ATCAATCTGT   60
AAAGTAAAAG CANTACATCC ACATTAACAT TATAACATCT TACAGTAATA TAAAAGCCAA   120
ATCATTGTTG GTACGTCATT TTCTTTAAAG TGAACAATTT AAGAAAACCT CACAAGAGTC   180
TGCACCTTGG AAAGATACGA TCAGAGTACA CAGTAGAGAC AAAACAGGCA TCTTCATTGT   240
AATTTTTTTT AATAAATAAA AGCACATTAA CAAAAAAGGA AGGTAAGCAG CACCGGAAGC   300
CTTTGACGTT TGTAATAAAA TGCTGGTACT CAATTGAATC GAGCTGGTTA AGTTTCACTA   360
GGAGGCGCNA AAAAGGAGCC GTTTTTGACT TAACATTTTA ATTCTAGTAG AGATAAGAAG   420
AGCTGTGTG GGCTTACAGT CCTTCACCTG ACTGTCCTTC ACCAGTGAGT AGCATACCAG   480
TTCTTCAAAT GTCCTATACT TTGGAAAGCA GACCCGACTC TGGAGCACTC GCCTTAATTA   540
GATTCTGAAT TTCCTTGAAT TTTGGATGGT CCTTATCAGC TACCAGCTGA AGCAGAACAG   600

```

CCTCACTCGT GGTCATATG ATCCCGGTTC G

631

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met	Val	Leu	Ile	Ser	Tyr	Gln	Leu	Lys	Gln	Asn	Ser	Leu	Thr	Arg	Gly
1				5					10					15	
His	Tyr	Asp	Pro	Gly	Ser										
				20											

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 70 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAAAAAAAA	AAAAAAAAA	AAAAAAAAA	AAAAAAAAA	AAAAAAAAA	AAAAAAAAA	60
AAAAAAAAA						70

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 428 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

WO 98/17687

AGCACGCGGT CCTGCCCCGTG GACGGGGCAA CGCTGGCAGA TGTGATGCGC CAGCGGGGCA 60
 TCAACATGCG CTACCTGGGC AAGGTGCTGG AGCTGGTGCT GCGGARCCCG GCCCGCCACC 120
 AGCTGGACCA CGTCTTTAAA ATCGGCATG GAGAACTCAT CACCCGCTCG SCCAAGCACA 180
 TCTTCAAGAC GTACTTACAG GGAGTCGAGC TCTCCGGCCT CTCAGCCGCC ATCAGCCACT 240
 TCCTGAACTG CTTCTTGAGC TCCTACCCAA ACCCCGTGGC CCACCTGCCC GCCGACGAGC 300
 TGGTCTCCAA GAAGCGGAAT AAGAGGAGGA AAAACCGGCC CCCGGGGGCT GCAGATAACA 360
 CAGCCTGGGC TGTCATGACC CCCCAGGAGC TCTGGAAGAA CATCTGCCAG GAGGCCAAGA 420
 ACTACTTT 428

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 128 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Arg Gln Arg Gly Ile Asn Met Arg Tyr Leu Gly Lys Val Leu Glu
 1 5 10 15
 Leu Val Leu Arg Xaa Pro Ala Arg His Gln Leu Asp His Val Phe Lys
 20 25 30
 Ile Gly Ile Gly Glu Leu Ile Thr Arg Ser Xaa Lys His Ile Phe Lys
 35 40 45
 Thr Tyr Leu Gln Gly Val Glu Leu Ser Gly Leu Ser Ala Ala Ile Ser
 50 55 60
 His Phe Leu Asn Cys Phe Leu Ser Ser Tyr Pro Asn Pro Val Ala His
 65 70 75 80
 Leu Pro Ala Asp Glu Leu Val Ser Lys Lys Arg Asn Lys Arg Arg Lys
 85 90 95
 Asn Arg Pro Pro Gly Ala Ala Asp Asn Thr Ala Trp Ala Val Met Thr
 100 105 110
 Pro Gln Glu Leu Trp Lys Asn Ile Cys Gln Glu Ala Lys Asn Tyr Phe
 115 120 125

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 245 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

TGGTGGGGGA GGATGTGCCC ACCCTGAGAC CCGGAGGAGA CGGGCNTTTG CCTGGGTTTG      60
CGGAGAGCCG CTTATGGGTG TGGTCCGTCC AGACACCTTG TTTCAAGGGG GATGGGCGTG      120
AGCGGGCAAG CAGAGCANCC CCACCGNTGA GCAAGAACTT TTTTGTGTTT TTAAACCATC      180
ACGTCCTCAT TTCACATTGG AATAAAGTGA GTTTTGTAAA AAAAAAAAAA AAAAAAAAAA      240
AAAAA                                           245

```

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 566 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```

CAGTGAGCCC TTTGAAAAAT AAACATCCAG ATGAAGATGC TGTGGAAGCT GAGGGGCATG      60
AGGTAAAAAG ACTCAGGTTT GACAAAGAAG GTGAAGTCAG AGAAACAGCC AGTCAAACGA      120
CTTCCAGCGA AATTTCTTCA GTTATGGTAG GAGAAACAGA AGCATCATCT TCATCTCAGG      180
ATAAAGACAA AGATAGCCGT TGTWCCCGGC AGCACTGTWC AGAAGAGGAT GAAGAAGAGG      240
ATGAAGAGGA AGAAGAAGAG TCTTTTATGA CATCAAGAGA AATGATCCCA GAAAGAAAAA      300
ATCAAGAAAA AGAATCTGAT GATGCCTTAA CTGTGAATGA AGAGACTTCT GAGGAAAATA      360
ATCAAATGGA GGAATCTGAT GTGTCTCAAG CTGAGAAAGA TTTGCTACAT TCTGAAGGTA      420
GTGAAAACGA AGGCCCTGTA AGTAGTAGTT CTTCTGACTG CCGTGAAACA GAAGAATTAG      480

```

WO 98/17687

TAGGATCCAA TTCCAGTAAA ACTGGAGAGA TTCTTTCAGA ATCATCCATG GAAAATGATG 540
 ACGAAGCCAC AGAAGTCACC GATGAA 566

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 141 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met Val Gly Glu Thr Glu Ala Ser Ser Ser Ser Gln Asp Lys Asp Lys
 1 5 10 15
 Asp Ser Arg Cys Xaa Arg Gln His Cys Xaa Glu Glu Asp Glu Glu Glu
 20 25 30
 Asp Glu Glu Glu Glu Glu Glu Ser Phe Met Thr Ser Arg Glu Met Ile
 35 40 45
 Pro Glu Arg Lys Asn Gln Glu Lys Glu Ser Asp Asp Ala Leu Thr Val
 50 55 60
 Asn Glu Glu Thr Ser Glu Glu Asn Asn Gln Met Glu Glu Ser Asp Val
 65 70 75 80
 Ser Gln Ala Glu Lys Asp Leu Leu His Ser Glu Gly Ser Glu Asn Glu
 85 90 95
 Gly Pro Val Ser Ser Ser Ser Ser Asp Cys Arg Glu Thr Glu Glu Leu
 100 105 110
 Val Gly Ser Asn Ser Ser Lys Thr Gly Glu Ile Leu Ser Glu Ser Ser
 115 120 125
 Met Glu Asn Asp Asp Glu Ala Thr Glu Val Thr Asp Glu
 130 135 140

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 531 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCATCATGGC TATAAATACC AAAACGATTT GGATCCATTT ATGTTTGTAG GATAATATAC	60
TACTGACTGA CTTGACTGTC AGGTTCACAA CAGCTAGATG ATATATTTAT GACTATGTCT	120
AATAGTTGAA ATAAATCTG AATATTGATT TACTATACCC AAGAGGGGAG AAAAATTAAC	180
CATTGTAAAT TTTTAAAAAT TTTTTCAAAA ATGTTAAAAAT GAGGCAAATT TAAGTTTACA	240
AATTTTGAAA TTTTCTTTTG AATATTTATG AAATTGTCAG TAAACTTACC TAAGATCCTG	300
TGACCTTTTG ATATTTTSTA TTTTAATTGT AGTGCCATGG ACCATTTGTA AACAAATTGA	360
TTTACTTTTG TTGGTTGTAA GTTGAAGATT TAGCATTATG ACTTTGAGGT CTGTGGTTTT	420
ATTTGTAAAC TTGCAATTGC TATATTTGCA AGGGCAAATG TATTTCTTTA TTAAATAAAG	480
TACAATAATG GTGAATGTAC CAAAATGACA TCACTTAAAA AAAAAAAAAA A	531

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1163 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

KCTGGAACCA CGCGGARGAA GGAAGAGACG CAGGCAGGCT GCGGTTACCC AAGCGGSCAC	60
CCGGGCCTCA GGGACCCCTC CCCGAGAGAC GGCACCATGA CCCAGGGAAA GCTCTCCGTG	120
GCTAACAAGC CCCTGGGACC GAGGGGCAGC AGCAKGTGCA TGGCGAGAAG AAGGAGCTCC	180
AGCAGTGCCC TCAGCCCCAC CCTCCTATGA GGAACCACCT CTGGGGAGGG GATGAAGGCA	240
GGGGCCTTCC CCCAGCCCC CACAGCGGTG CCTCTCCACC CTAGCTGGGC CTATGTGGAC	300
CCCAGCAGCA GCTCCAGCTA TGACAACGGT TTCCCCACCG GAGACCATGA GCTCTTCACC	360
ACTTTCAGCT GGGATGACCA GAAAGTTCGT CGAGTCTTTG TCAGAAAGGT CTACACCATC	420
CTGCTGATTC AGCTGCTGGT GACCTTGGCT GTCGTGGCTC TCTTTACTTT CTGTGACCCT	480
GTCAAGGACT ATGTCCAGGC CAACCCAGGC TGGTACTGGG CATCCTATGC TGTGTTCTTT	540
GCAACCTACC TGACCCTGGC TTGCTGTTCT GGACCCAGGA GGCATTTCCT CTGGAACCTG	600

WO 98/17687

```

ATTCTCCTGA CCGTCTTTAC CCTGTCCATG GCCTACCTCA CTGGGATGCT GTCCAGCTAC      660
TACAACACCA CCTCCGTGCT GCTGTGCCTG GGCATCACGG CCCTTGTCTG CCTCTCAGTC      720
ACCGTCTTCA GCTTCCAGAC CAAGTTCGAC TTCACCTCCT GCCAGGGCGT GCTCTTCGTG      780
CTTCTCATGA CTCTTTTCTT CAGCGGACTC ATCCTGGCCA TCCTCCTACC CTTCCAATAT      840
GTGCCCTGGC TCCATGCAGT TTATGCAGCA CTGGGAGCGG GTGTATTAC ATTGTTCTCTG      900
GCACTTGACA CCCAGTTGCT GATGGGTAAC CGACGCCACT CGCTGAGCCC TGAGGAGTAT      960
ATTTTGGAG CCCTCAACAT TTACCTAGAC ATCATCTATA TCTTCACCTT CTTCTGCAG      1020
CTTTTGGCA CTAACCGAGA ATGAGGAGCC CTCCCTGCCC CACCGTCCTC CAGAGAATGC      1080
GCCCCCTCTG GTTCCCTGTC CCTCCCCTGC GCTCCTGCCA GACCAGATAT AAAACTAGCT      1140
GCCAACCCAA AAAAAAAAAA AAA                                             1163

```

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 270 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

Met Lys Ala Gly Ala Phe Pro Pro Ala Pro Thr Ala Val Pro Leu His
1           5           10           15
Pro Ser Trp Ala Tyr Val Asp Pro Ser Ser Ser Ser Tyr Asp Asn
20           25           30
Gly Phe Pro Thr Gly Asp His Glu Leu Phe Thr Thr Phe Ser Trp Asp
35           40           45
Asp Gln Lys Val Arg Arg Val Phe Val Arg Lys Val Tyr Thr Ile Leu
50           55           60
Leu Ile Gln Leu Leu Val Thr Leu Ala Val Val Ala Leu Phe Thr Phe
65           70           75           80
Cys Asp Pro Val Lys Asp Tyr Val Gln Ala Asn Pro Gly Trp Tyr Trp
85           90           95
Ala Ser Tyr Ala Val Phe Phe Ala Thr Tyr Leu Thr Leu Ala Cys Cys
100          105          110

```

Ser	Gly	Pro	Arg	Arg	His	Phe	Pro	Trp	Asn	Leu	Ile	Leu	Leu	Thr	Val	115	120	125	
Phe	Thr	Leu	Ser	Met	Ala	Tyr	Leu	Thr	Gly	Met	Leu	Ser	Ser	Tyr	Tyr	130	135	140	
Asn	Thr	Thr	Ser	Val	Leu	Leu	Cys	Leu	Gly	Ile	Thr	Ala	Leu	Val	Cys	145	150	155	160
Leu	Ser	Val	Thr	Val	Phe	Ser	Phe	Gln	Thr	Lys	Phe	Asp	Phe	Thr	Ser	165	170	175	
Cys	Gln	Gly	Val	Leu	Phe	Val	Leu	Leu	Met	Thr	Leu	Phe	Phe	Ser	Gly	180	185	190	
Leu	Ile	Leu	Ala	Ile	Leu	Leu	Pro	Phe	Gln	Tyr	Val	Pro	Trp	Leu	His	195	200	205	
Ala	Val	Tyr	Ala	Ala	Leu	Gly	Ala	Gly	Val	Phe	Thr	Leu	Phe	Leu	Ala	210	215	220	
Leu	Asp	Thr	Gln	Leu	Leu	Met	Gly	Asn	Arg	Arg	His	Ser	Leu	Ser	Pro	225	230	235	240
Glu	Glu	Tyr	Ile	Phe	Gly	Ala	Leu	Asn	Ile	Tyr	Leu	Asp	Ile	Ile	Tyr	245	250	255	
Ile	Phe	Thr	Phe	Phe	Leu	Gln	Leu	Phe	Gly	Thr	Asn	Arg	Glu	260	265	270			

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 624 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CGCACCCCT CCGCCGCGG GCGCAKCGG GCGCTGGTG GAKCTGMGAA GGGCCASGTC	60
CGGCGGGCGG GCGGCGGCT GGCCTGGCT CCGACTCTG CCCGCCAGG GCGGCGGTC	120
CANCCGGGAG GGCGACGTGG AGCGGCCACK TGGAKCGGCC CGGGGGARGC TGGCGGCGGG	180
AKGCGAGGCG CGGGCGGCGC AKCAKCCAKG AGCGCCACG GAGSTGGACC CCCAGAKCCG	240
CGCGGCGCCG CAGCAGTTCC AGGAAGGATG TTACCTTTGA CGATGACAGT GTTAATCTCTG	300
CTGCTGCTCC CCACGGGTCA GGCTGCCCCA AAGGATGGAG TCACAAGGCC AGAATCTGAA	360

```

GTGCAGCATC AGCTCCTGCC CAACCCCTTC CAGCCAGGCC AGGAGCAGET CGGACTTCTG      420
CAGAGCTACC TAAAGGGACT AGGAAGGACA GAAGTGCAAC TGGAGCATCT GAGCCGGGAG      480
CAGGTTCTCC TCTACCTCTT TGCCCTCCAT GACTATGACC AGAGTGGACA GCTGGATGGC      540
CTGGAGCTGC TGTCCATGTT GACAGCTGCT CTGGCCCCTG GAGCTGCCAA CTCTCCTACC      600
ACCAACCCGG TGATCTTGAT AGTG                                             624

```

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 119 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```

Met Leu Pro Leu Thr Met Thr Val Leu Ile Leu Leu Leu Leu Pro Thr
1           5           10           15
Gly Gln Ala Ala Pro Lys Asp Gly Val Thr Arg Pro Glu Ser Glu Val
20           25           30
Gln His Gln Leu Leu Pro Asn Pro Phe Gln Pro Gly Gln Glu Gln Leu
35           40           45
Gly Leu Leu Gln Ser Tyr Leu Lys Gly Leu Gly Arg Thr Glu Val Gln
50           55           60
Leu Glu His Leu Ser Arg Glu Gln Val Leu Leu Tyr Leu Phe Ala Leu
65           70           75           80
His Asp Tyr Asp Gln Ser Gly Gln Leu Asp Gly Leu Glu Leu Leu Ser
85           90           95
Met Leu Thr Ala Ala Leu Ala Pro Gly Ala Ala Asn Ser Pro Thr Thr
100          105          110
Asn Pro Val Ile Leu Ile Val
115

```

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 80 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA      60
AAAAAAAAA AAAAAAAAAA                                         80
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2161 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```
AGACAGGGAA TACTTTATTC AAAACCCATC ACAGAAATGG ACAGCTTGGG TCTGTAACAA      60
AGCATTCATG TTTTAGAGCA TAGGTCAGTA ATTGTATATG AGAGCATACA CTGCTACATA      120
CAAATTAAct GATCAGACCA CAACTTTTCA ATGTTTAAAA CAGAATAAGC TTCCCTGTAA      180
AAGCAGCACC TTTGTGACGT TTAACTTTTA GTATTCCTCT CCTTCTTCCT CACCCCTCTCC      240
TTCAACAGAA TCCACACCAA CCTCCTCATA ATCCTTCCTC GCAGCACATG AATCACAGGT      300
ATTCCTACTG CAAGCGGGAG GCGGARGARC GGAAGCGGC GGARCGGAR GCGCGCGAGA      360
AAGGGCACTT GGAACCCACC GAGCTGCTGA TGAACCGGC TTACTTGCAG AGCATTACCC      420
CTCAGGGGTA CTCTGACTCG GAGGAGAGGG AGAGTATGCC GAGGGATGGC GAGAGCGAGA      480
AGGAGCACGA GAAAGAAGGC GAGGATGGCT ACGGGAAGCT GGGCAGACAG GATGGCGACG      540
AGGAGTTCGA GGAGGAAGAG GAAGAAAGTG AAAATAAAAG TATGGATACG GATCCCGAAA      600
CGATACGAGA TGAAAAAGAG ACTGGAGATC ACTCCATGGA CGATAGTTCG GAGGATGGGA      660
AAATGGAAAC CAAATCAGAC CACGAGGAAG ACAATATGGA AGATGGCATG TAATAAACTA      720
CTGCATTTTA AGCTTCCTAT TTTTTTTTCC AGTAGTATTG TTACCTGCTT GAAAACACTG      780
CTGTGTTAAG CTGTTCATGC ACGTGCCTGA CGCTTCAGG AAGCTGTAGA GAGGGACAGA      840
AGGGGCGGTT CAGCCAAGAC AGATGTWGAC GGAGTTGGAG CTGGGTATTG TTAAAAACTG      900
```

CATTATGCAA AAATTTTGTA CAGTGTTAAG GCCTAAAAAC TGTGTGGTTC AGAGACTAAT 960
 TCCTGTGTTT AATAGCATTT ATACTTTAAG CACAAC TAGA AAATTGTAAG AATTGCACTC 1020
 TACTTATGTA TCACTACAAA CTTTAAAAAA CTATGTCTAA TTTATATTAA TACATTTTAA 1080
 AAAGGTGCCC GCACTACCAT ACATCAGTAT TTTTATTATT ATTATTGTTA TTCCTTTTAA 1140
 ATTTAATGTG CTCGCACTAC AATGCATCAG TATTATGATT CCTCTGTACT TTCCTTTTCGC 1200
 TATTCATCAA TTTCCCATTT TTTTTCAG CTTAAGTAAC CACACAATTT TAGGCCTCAA 1260
 TTTTTCCTTT TCTGTGAAGG AACTTGAAGT GATGCATGTG TGAATTTAAG ATACCGAAGT 1320
 CTTAAAGTGA CCTGGACGTG AAGGAAAAAG TAAGATGAGA AATAAAGAAA GCCTTTGTAA 1380
 GGTGGTTTTA AAAGCCTTAT ATGCAAACCT TTTAATCTGT GTTTCCTGCA GTGCCATCCT 1440
 TGTACAGTGT TAAGAGGGTA ACATGGGTTA CCTTTCACC AGCTTCAGTG TTAAGCTCAC 1500
 CCTGTCTTTT GAAGCACCCA TGTCAGTATT AGAAGAATAG GCAGCAGTTC CTTAGTTTAC 1560
 ATATGTTTGT GCAATTATTT TCTGTACTTT TTTGTTTATT AATTTTGTCA GTATTACACC 1620
 AAAGTGTGTT TGCAACAAAA AAATTTTTTTT TGCATTCATT TAATTTTAGG TCAAATAACA 1680
 TTTTATTTAT GTGGCTCATT TTATATTTCC TAATTTTATT TATTTTCATAC TGTAGTGTAC 1740
 AGTATTATAG TTCTTCAATA TATAGATATA TTTTAGTAAA AAAGGAACAT GACGTTGATC 1800
 ATTTGGGCAA ATTTTACGTA AAGAGAAGAG CATTTATTGT GTTTTGAAC ATTAATTGTG 1860
 AGATGGGATT TTTCAATTTT ATTATTTTAT TTTTGTTCCT TTCCAATTAC TGGAAATTCC 1920
 AAATTTGGGA ACTTTTGATA CGATCTTGTG AAAACACTGT ATTTTCGACT GAAAATTCCA 1980
 CTTTCTTCAT CTTGTTTTTT AGCTAAAAAG AGGGACTGTT AAATACAATG TATGATACCA 2040
 TGACAAAAAT CTTTCCTGAA TTGTCCTTTG TAAAAGTATT ATTGAATTTT CAATTTGTAA 2100
 TTTCTTTTGA AAATGACCAT GCTCGAATAA AAATGTAGCC AAATAAAAAA AAAAAAAAAA 2160
 A 2161

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 141 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Met Asn His Arg Tyr Ser Tyr Cys Lys Arg Glu Ala Glu Glu Arg Glu
 1 5 10 15

Ala Ala Glu Arg Glu Ala Arg Glu Lys Gly His Leu Glu Pro Thr Glu
 20 25 30

Leu Leu Met Asn Arg Ala Tyr Leu Gln Ser Ile Thr Pro Gln Gly Tyr
 35 40 45

Ser Asp Ser Glu Glu Arg Glu Ser Met Pro Arg Asp Gly Glu Ser Glu
 50 55 60

Lys Glu His Glu Lys Glu Gly Glu Asp Gly Tyr Gly Lys Leu Gly Arg
 65 70 75 80

Gln Asp Gly Asp Glu Glu Phe Glu Glu Glu Glu Glu Ser Glu Asn
 85 90 95

Lys Ser Met Asp Thr Asp Pro Glu Thr Ile Arg Asp Glu Lys Glu Thr
 100 105 110

Gly Asp His Ser Met Asp Asp Ser Ser Glu Asp Gly Lys Met Glu Thr
 115 120 125

Lys Ser Asp His Glu Glu Asp Asn Met Glu Asp Gly Met
 130 135 140

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2169 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GCAGTTACTG GGARGGGGCT TGCTGTGGCC CTGTCAGGAA RARTAGAGCT CTGGTCCAGC 60

TCCGCGCAGG GAGGGAGGCT GTCACCATGC CGGCCTGCTG CAGCTGCAGT GATGTTTTCC 120

AGTATGAGAC GAACAAAGTC ACTCGGATCC AGAGCATGAA TTATGGCACC ATTAAGTGGT 180

TCTTCCACGT GATCATCTTT TCCTACGTTT GCTTTGCTCT GGTGAGTGAC AAGCTGTACC 240

AGCGGAAAGA GCCTGTCATC AGTTCTGTGC ACACCAAGGT GAAGGGGATA GCAGARGTGA 300

AAGAGGAGAT CGTGGAGAAT GGAGTGAAGA AGTTGGTGCA CAGTGTCTTT GACACCGCAG 360

ACTACACCTT CCCTTTGCAG GGGAACCTTT TCTTCGTGAT GACAACTTT CTCAAAACAG 420
 AAGGCCAAGA GCAGCGGTTG TGTCCCGAGT ATCCCACCCG CAGGACGSTS TGTTCYTCTG 480
 ACCGAGGTTG WAAAAAGGGA TGGATGGACC CGCAGAGCAA AGGAATTCAG ACCGGAAGGT 540
 GTGTAGTGCA TGAAGGGAAC CAGAAGACYT GTGAAGTCTY TGCCTGGWGC CCCATSGAGG 600
 CAGTGGAAGA GGCCCCCGG CCTGCTYTCT TGAACAGTGC CGAAACTTC ACTGTGCTCA 660
 TCAAGAACAA TATCGACTTC CCCGGCCACA ACTACACCAC GAGAAACATC CTGCCAGGTT 720
 TAAACATCAC TTGTACCTTC CACAAGACTC AGAATCCACA GTGTCCCATT TTCCGACTAG 780
 GAGACATCTT CCGAGAAACA GGCGATAATT TTTCAGATGT GGCAATTCAG GGCGGAATAA 840
 TGGGCATTGA GATCTACTGG GACTGCAACC TAGACCGTTG GTTCCATCAC TGCCATCCCA 900
 AATACAGTTT CCGTCGCCCT GACGACAAGA CCACCAACGT GTCCTGTAC CCTGGCTACA 960
 ACTTCAGATA CGCCAAGTAC TACAAGGAAA ACAATGTTGA GAAACGGA CTGATAAAAG 1020
 TCTTCGGGAT CCGTTTTGAC ATCCTGGTTT TTGGCACCGG AGGAAAATTT GACATTATCC 1080
 AGCTGGTTGT GTACATCGGC TCAACCTCT CCTACTTCGG TCTGGCCGCT GTGTTTCATCG 1140
 ACTTCCTCAT CGACACTTAC TCCAGTAACT GCTGTGCTC CCATATTTAT CCCTGGTGCA 1200
 AGTGCTGTCA GCCCTGTGTG GTCAACGAAT ACTACTACAG GAAGAAGTGC GAGTCCATTG 1260
 TGGAGCCAAA GCCGACATTA AAGTATGTGT CCTTGTGGA TGAATCCAC ATTAGGATGG 1320
 TGAACCAGCA GCTACTAGGG AGAAGTCTGC AAGATGTCAA GGGCCAAGAA GTCCCAAGAC 1380
 CTGCGATGGA CTTACAGAT TTGTCCAGGC TGCCCCGGC CCTCCATGAC ACACCCCGA 1440
 TTCTTGACA ACCAGAGGAG ATACAGCTGC TTAGAAAGGA GGCGACTCCT AGATCCAGGG 1500
 ATAGCCCCGT CTGGTGCCAG TGTGGAAGCT GCCTCCCATC TCAACTCCCT GAGAGCCACA 1560
 GGTGCCTGGA GGAGCTGTGC TGCCGGAAAA AGCCGGGGGC CTGCATCACC ACCTCAGAGC 1620
 TGTTCAGGAA GCTGGTCCTG TCCAGACACG TCCTGCAGTT CCTCCTGCTC TACCAGGAGC 1680
 CCTTGCTGGC GCTGGATGTG GATTCCACCA ACAGCCGGCT GCGGCACTGT GCCTACAGGT 1740
 GCTACGCCAC CTGGCGCTTC GGCTCCCAGG ACATGGCTGA CTTTGCCATC CTGCCCAGCT 1800
 GCTGCCGCTG GAGGATCCGG AAAGAGTTTC CGAAGAGTGA AGGGCAGTAC AGTGGCTTCA 1860
 AGAGTCCTTA CTGAAGCCAG GCACCGTGGC TMACGTCTGT AATCCCAGCG CTTTGGGAGG 1920
 CCGAGGCAGG CAGATCACCT GAGGTCGGGA GTTGAGACC CGCCTGGCTA ACAAGGCGAA 1980
 ATCCTGTCTG TACTAAAAAT AAAAAATCA GCCAGACATG GTGGCATGCA CCTGCAATCC 2040

CAGCTACTCG GGAGGCTGAG GCACAAGAAT CACTTGAACC CGGGAGGCAG AGGTTGTAGT 2100
 GAGCCCAGAT TGTGCCACTG CTYTCCAGCC TGGGAGGCAC AGCAAAGTGT CCCCCAAAAA 2160
 AAAAAAAA 2169

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 595 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met	Pro	Ala	Cys	Cys	Ser	Cys	Ser	Asp	Val	Phe	Gln	Tyr	Glu	Thr	Asn	1	5	10	15
Lys	Val	Thr	Arg	Ile	Gln	Ser	Met	Asn	Tyr	Gly	Thr	Ile	Lys	Trp	Phe	20	25	30	
Phe	His	Val	Ile	Ile	Phe	Ser	Tyr	Val	Cys	Phe	Ala	Leu	Val	Ser	Asp	35	40	45	
Lys	Leu	Tyr	Gln	Arg	Lys	Glu	Pro	Val	Ile	Ser	Ser	Val	His	Thr	Lys	50	55	60	
Val	Lys	Gly	Ile	Ala	Glu	Val	Lys	Glu	Glu	Ile	Val	Glu	Asn	Gly	Val	65	70	75	80
Lys	Lys	Leu	Val	His	Ser	Val	Phe	Asp	Thr	Ala	Asp	Tyr	Thr	Phe	Pro	85	90	95	
Leu	Gln	Gly	Asn	Ser	Phe	Phe	Val	Met	Thr	Asn	Phe	Leu	Lys	Thr	Glu	100	105	110	
Gly	Gln	Glu	Gln	Arg	Leu	Cys	Pro	Glu	Tyr	Pro	Thr	Arg	Arg	Thr	Xaa	115	120	125	
Cys	Ser	Ser	Asp	Arg	Gly	Xaa	Lys	Lys	Gly	Trp	Met	Asp	Pro	Gln	Ser	130	135	140	
Lys	Gly	Ile	Gln	Thr	Gly	Arg	Cys	Val	Val	His	Glu	Gly	Asn	Gln	Lys	145	150	155	160
Thr	Cys	Glu	Val	Xaa	Ala	Trp	Xaa	Pro	Xaa	Glu	Ala	Val	Glu	Glu	Ala	165	170	175	
Pro	Arg	Pro	Ala	Xaa	Leu	Asn	Ser	Ala	Glu	Asn	Phe	Thr	Val	Leu	Ile	180	185	190	

Lys Asn Asn Ile Asp Phe Pro Gly His Asn Tyr Thr Thr Arg Asn Ile
 195 200 205
 Leu Pro Gly Leu Asn Ile Thr Cys Thr Phe His Lys Thr Gln Asn Pro
 210 215 220
 Gln Cys Pro Ile Phe Arg Leu Gly Asp Ile Phe Arg Glu Thr Gly Asp
 225 230 235 240
 Asn Phe Ser Asp Val Ala Ile Gln Gly Gly Ile Met Gly Ile Glu Ile
 245 250 255
 Tyr Trp Asp Cys Asn Leu Asp Arg Trp Phe His His Cys His Pro Lys
 260 265 270
 Tyr Ser Phe Arg Arg Leu Asp Asp Lys Thr Thr Asn Val Ser Leu Tyr
 275 280 285
 Pro Gly Tyr Asn Phe Arg Tyr Ala Lys Tyr Tyr Lys Glu Asn Asn Val
 290 295 300
 Glu Lys Arg Thr Leu Ile Lys Val Phe Gly Ile Arg Phe Asp Ile Leu
 305 310 315 320
 Val Phe Gly Thr Gly Gly Lys Phe Asp Ile Ile Gln Leu Val Val Tyr
 325 330 335
 Ile Gly Ser Thr Leu Ser Tyr Phe Gly Leu Ala Ala Val Phe Ile Asp
 340 345 350
 Phe Leu Ile Asp Thr Tyr Ser Ser Asn Cys Cys Arg Ser His Ile Tyr
 355 360 365
 Pro Trp Cys Lys Cys Cys Gln Pro Cys Val Val Asn Glu Tyr Tyr Tyr
 370 375 380
 Arg Lys Lys Cys Glu Ser Ile Val Glu Pro Lys Pro Thr Leu Lys Tyr
 385 390 395 400
 Val Ser Phe Val Asp Glu Ser His Ile Arg Met Val Asn Gln Gln Leu
 405 410 415
 Leu Gly Arg Ser Leu Gln Asp Val Lys Gly Gln Glu Val Pro Arg Pro
 420 425 430
 Ala Met Asp Phe Thr Asp Leu Ser Arg Leu Pro Leu Ala Leu His Asp
 435 440 445
 Thr Pro Pro Ile Pro Gly Gln Pro Glu Glu Ile Gln Leu Leu Arg Lys
 450 455 460
 Glu Ala Thr Pro Arg Ser Arg Asp Ser Pro Val Trp Cys Gln Cys Gly
 465 470 475 480
 Ser Cys Leu Pro Ser Gln Leu Pro Glu Ser His Arg Cys Leu Glu Glu
 485 490 495

Leu Cys Cys Arg Lys Lys Pro Gly Ala Cys Ile Thr Thr Ser Glu Leu
 500 505 510
 Phe Arg Lys Leu Val Leu Ser Arg His Val Leu Gln Phe Leu Leu Leu
 515 520 525
 Tyr Gln Glu Pro Leu Leu Ala Leu Asp Val Asp Ser Thr Asn Ser Arg
 530 535 540
 Leu Arg His Cys Ala Tyr Arg Cys Tyr Ala Thr Trp Arg Phe Gly Ser
 545 550 555 560
 Gln Asp Met Ala Asp Phe Ala Ile Leu Pro Ser Cys Cys Arg Trp Arg
 565 570 575
 Ile Arg Lys Glu Phe Pro Lys Ser Glu Gly Gln Tyr Ser Gly Phe Lys
 580 585 590
 Ser Pro Tyr
 595

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GNGTGAAGTCT TCCTGGGAAC CATAATCT

29

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TNTTCCCTGAA GAGCTGGAGA GGTGCTAA

29

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GNTCTACCATG TGAAGAAGGA ACGCAAAA

29

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TNGGCAAAGCT GTGCTGCAGG ATAGAGTG

29

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

ANGTGAAGGAC TGTAAGCCCA CACAAGCT

29

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TNATGACAGCC CAGGCTGTGT TATCTGCA

29

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CNGGGCCTTCG TTTTCACTAC CTTCAGAA

29

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

TNAAGACGGTG ACTGAGAGGC AGACAAGG

29

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

TNCCTAGTCCC TTTAGGTAGC TCTGCAGA

29

- (2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GNGCACGAGAA AGAAGGCGAG GATGGCTA

29

- (2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "oligonucleotide"

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

TNGGACACTGT GGATTCTGAG TCTTGTGG

29

What is claimed is:

1. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 437 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 515 to nucleotide 1159;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 539 to nucleotide 1099;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AR415_4 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AR415_4 deposited under accession number ATCC 98232;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AR415_4 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AR415_4 deposited under accession number ATCC 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

2. A composition of claim 1 wherein said polynucleotide is operably linked to an expression control sequence.

3. A host cell transformed with a composition of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein, which comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying the protein from the culture.
6. A protein produced according to the process of claim 5.
7. The protein of claim 6 comprising a mature protein.
8. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;
 - (b) the amino acid sequence of SEQ ID NO:2 from amino acid 51 to amino acid 221;
 - (c) fragments of the amino acid sequence of SEQ ID NO:2; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone AR415_4 deposited under accession number ATCC 98232;the protein being substantially free from other mammalian proteins.
9. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
10. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 51 to amino acid 221.
11. The composition of claim 8, further comprising a pharmaceutically acceptable carrier.

12. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 11.

13. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.

14. A composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 59 to nucleotide 376;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 179 to nucleotide 376;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AS63_29 deposited under accession number ATCC 98232;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AS63_29 deposited under accession number ATCC 98232;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AS63_29 deposited under accession number ATCC 98232;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AS63_29 deposited under accession number ATCC 98232;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

15. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:4;
 - (b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 91;
 - (c) fragments of the amino acid sequence of SEQ ID NO:4; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone AS63_29 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.
16. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3 or SEQ ID NO:5.
17. A composition comprising an isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 198 to nucleotide 2039;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 490 to nucleotide 809;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AY304_14 deposited under accession number ATCC xxxxx;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx;
 - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AY304_14 deposited under accession number ATCC xxxxx;
 - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

18. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:7;
- (b) the amino acid sequence of SEQ ID NO:7 from amino acid 126 to amino acid 204;
- (c) the amino acid sequence of SEQ ID NO:7 from amino acid 106 to amino acid 204;
- (d) fragments of the amino acid sequence of SEQ ID NO:7; and
- (e) the amino acid sequence encoded by the cDNA insert of clone AY304_14 deposited under accession number ATCC xxxxx;

the protein being substantially free from other mammalian proteins.

19. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:6.

20. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 102 to nucleotide 2027;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 1902 to nucleotide 2027;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 1 to nucleotide 431;

- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BG160_1 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

21. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:9;
 - (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 110;
 - (c) fragments of the amino acid sequence of SEQ ID NO:9; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone BG160_1 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.

22. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:8.

23. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 566 to nucleotide 631;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO432_4 deposited under accession number ATCC 98232;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BO432_4 deposited under accession number ATCC 98232;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BO432_4 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BO432_4 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
- (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

24. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
 - (b) fragments of the amino acid sequence of SEQ ID NO:12; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone BO432_4 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.

25. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11, SEQ ID NO:10 or SEQ ID NO:13 .
26. A composition comprising an isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:14 from nucleotide 45 to nucleotide 428;
 - (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO538_2 deposited under accession number ATCC 98232;
 - (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232;
 - (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BO538_2 deposited under accession number ATCC 98232;
 - (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232;
 - (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:15;
 - (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:15 having biological activity;
 - (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
 - (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
 - (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
27. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:15;

- (b) the amino acid sequence of SEQ ID NO:15 from amino acid 52 to amino acid 128;
 - (c) fragments of the amino acid sequence of SEQ ID NO:15; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone BO538_2 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.

28. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:14 or SEQ ID NO:16.

29. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 144 to nucleotide 566;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BR595_4 deposited under accession number ATCC 98232;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BR595_4 deposited under accession number ATCC 98232;
- (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BR595_4 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BR595_4 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).

30. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
 - (b) the amino acid sequence of SEQ ID NO:18 from amino acid 39 to amino acid 141;
 - (c) fragments of the amino acid sequence of SEQ ID NO:18; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone BR595_4 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.

31. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:17 or SEQ ID NO:19.

32. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 232 to nucleotide 1041;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 460 to nucleotide 1041;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 590 to nucleotide 1163;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI490_2 deposited under accession number ATCC 98232;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI490_2 deposited under accession number ATCC 98232;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CI490_2 deposited under accession number ATCC 98232;

- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CI490_2 deposited under accession number ATCC 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).

33. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:21;
- (b) the amino acid sequence of SEQ ID NO:21 from amino acid 133 to amino acid 270;
- (c) fragments of the amino acid sequence of SEQ ID NO:21; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CI490_2 deposited under accession number ATCC 98232;

the protein being substantially free from other mammalian proteins.

34. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:20.

35. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:22;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:22 from nucleotide 268 to nucleotide 624;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:22 from nucleotide 325 to nucleotide 624;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI522_1 deposited under accession number ATCC 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI522_1 deposited under accession number ATCC 98232;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CI522_1 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CI522_1 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:23;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:23 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

36. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:23;
 - (b) fragments of the amino acid sequence of SEQ ID NO:23; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone CI522_1 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.

37. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:22 or SEQ ID NO:24.

38. A composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 288 to nucleotide 713;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 686 to nucleotide 968;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CN238_1 deposited under accession number ATCC 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CN238_1 deposited under accession number ATCC 98232;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).

39. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:26;
- (b) fragments of the amino acid sequence of SEQ ID NO:26; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CN238_1 deposited under accession number ATCC 98232;


the protein being substantially free from other mammalian proteins.

40. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:25.
41. A composition comprising an isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 87 to nucleotide 1874;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 452 to nucleotide 830;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO390_1 deposited under accession number ATCC 98232;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232;
 - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CO390_1 deposited under accession number ATCC 98232;
 - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
 - (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
42. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:28;

- (b) the amino acid sequence of SEQ ID NO:28 from amino acid 140 to amino acid 248;
 - (c) fragments of the amino acid sequence of SEQ ID NO:28; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone CO390_1 deposited under accession number ATCC 98232;
- the protein being substantially free from other mammalian proteins.

43. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:27.

FIGURE 1A




Plasmid name: pED6dpc2

Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs
 Plasmid size: 4529 bp

Comments/References: pNOTs is a derivative of pMT2 (Kaufman et al, 1989. Mol. Cell. Biol. 9: 1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the Clal site. SST cDNAs are cloned between EcoRI and NotI

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, 5/10, C07K 14/47, C12Q 1/68, A61K 38/17		A3		(11) International Publication Number: WO 98/17687
(21) International Application Number: PCT/US97/19590		(43) International Publication Date: 30 April 1998 (30.04.98)		
(22) International Filing Date: 24 October 1997 (24.10.97)				
(30) Priority Data: 08/740,274 25 October 1996 (25.10.96) US Not furnished 24 October 1997 (24.10.97) US				
(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).				
(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 90 Green Meadow Drive, Tewksbury, MA 01876 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US).				
(74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).				
		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).		
		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>		
		(88) Date of publication of the international search report: 30 July 1998 (30.07.98)		

(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

(57) Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.



Plasmid name: pED6dpc2
Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. GST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/19590

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N5/10 C07K14/47 C12Q1/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	L. HILLIER ET AL.: "zf04h10.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 37600 3'" EMBL SEQUENCE DATABASE, 28 August 1996, HEIDELBERG, FRG, XP002054789 Accession no. AA037886	13
X	L. HILLIER ET AL.: "zf04h10.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 376003 5'" EMBL SEQUENCE DATABASE, 28 August 1996, HEIDELBERG, FRG, XP002054790 Accession no. AA037885	13

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

6 February 1998

Date of mailing of the international search report

08.06.98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

HORNIG H.

INTERNATIONAL SEARCH REPORT

Intern 1al Application No
PCT/US 97/19590

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	L. HILLIER ET AL.: "yu67a12.r1 Homo sapiens cDNA clone 238846 5'" EMBL SEQUENCE DATABASE, 19 October 1995, HEIDELBERG, FRG, XP002054791 Accession no. H64488 ---	13
A	ADAMS M D ET AL: "3,400 NEW EXPRESSED SEQUENCE TAGS IDENTIFY DIVERSITY OF TRANSCRIPTS IN HUMAN BRAIN" NATURE GENETICS, vol. 4, no. 3, pages 256-267, XP000611495 see the whole document ---	1-13
A	JACOBS K ET AL: "A novel method for isolating eukaryotic cDNA clones encoding secreted proteins." KEYSTONE SYMPOSIUM ON DENDRITIC CELLS: ANTIGEN PRESENTING CELLS OF T AND B LYMPHOCYTES, TAOS, NEW MEXICO, USA, MARCH 10-16, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21A). 1995. 19. ISSN: 0733-1959, XP002027246 abstract no. C1-207 see abstract ---	1-13
A	EP 0 510 691 A (OSAKA BIOSCIENCE INST) 28 October 1992 see the whole document ---	1-13
A	WO 94 07916 A (MERCK & CO INC ;SCHMIDT AZRIEL (US); RODAN GIDEON A (US); RUTLEDGE) 14 April 1994 see the whole document ---	1-13
A	WO 90 05780 A (OREGON STATE) 31 May 1990 see the whole document ---	1-13
A	WO 90 14432 A (GENETICS INST) 29 November 1990 see the whole document ---	1-13
A	WO 96 17925 A (IMMUNEX CORP) 13 June 1996 see the whole document ---	1-13
A	R.J. KAUFMAN ET AL.: "Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in chinese hamster ovary cells" MOL. CELL. BIOL., vol. 9, no. 3, March 1989, ASM WASHINGTON, DC,US, pages 1233-1242, XP002041592 see the whole document ---	1-13
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/19590

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	R.J. KAUFMAN ET AL.: "The phosphorylation state of eucaryotic initiation factor 2 alters translation efficiency of specific mRNAs" MOL. CELL. BIOL., vol. 9, no. 3, March 1989, ASM WASHINGTON, DC,US, pages 946-958, XP002041593 see the whole document ---	1-13
A	R.J. KAUFMAN ET AL.: "Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus" NUCLEIC ACIDS RESEARCH, vol. 19, no. 16, 1991, IRL PRESS LIMITED,OXFORD,ENGLAND, pages 4485-4490, XP002041594 cited in the application see the whole document ---	1-13
A	US 5 536 637 A (JACOBS KENNETH) 16 July 1996 cited in the application see the whole document ---	1-13
P,A	WO 97 07198 A (GENETICS INSTITUT) 27 February 1997 see the whole document ---	1-13
P,A	WO 97 25427 A (GENETICS INST) 17 July 1997 see the whole document -----	1-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 19590

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see continuation-sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-13

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 97/19590

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-13

A composition comprising an isolated polynucleotide sequence of SEQ ID no.1; said composition wherein said polynucleotide sequence is operably linked to an expression control sequence; a host cell transformed with said composition; a process for producing a protein comprising growing a culture of said host cell and purifying said protein from the culture; a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from SEQ ID no.2; said composition further comprises a pharmaceutically acceptable carrier; a method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of said composition; an isolated gene corresponding to the cDNA sequence of SEQ ID no.1;

2. Claims: 14-16

A composition comprising an isolated protein encoded by a polynucleotide sequence selected from the group of SEQ ID no.3; a composition comprises a protein, wherein said protein comprises an amino acid sequence selected from the group of SEQ ID no.4; an isolated gene corresponding to the cDNA sequence of SEQ ID nos. 3 and 5;

3. Claims: 17-19

Idem as subject 2 but limited to SEQ ID nos. 6 and 7.

4. Claims: 20-22

Idem as subject 2 but limited to SEQ ID nos. 8 and 9.

5. Claims: 23-25

Idem as subject 2 but limited to SEQ ID nos. 10,11,12 and 13.

6. Claims: 26-28

Idem as subject 2 but limited to SEQ ID nos. 14,15 and 16.

7. Claims: 29-31

Idem as subject 2 but limited to SEQ ID nos. 17,18 and 19.

8. Claims: 32-34

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 97 / 19590

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Idem as subject 2 but limited to SEQ ID nos. 20 and 21.

9. Claims: 35-37

Idem as subject 2 but limited to SEQ ID nos. 22,23 and 24.

10. Claims: 38-40

Idem as subject 2 but limited to SEQ ID nos. 25 and 26.

11. Claims: 41-43

Idem as subject 2 but limited to SEQ ID nos. 27 and 28.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/19590

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0510691 A	28-10-92	CA 2067031 A JP 5184368 A	27-10-92 27-07-93
WO 9407916 A	14-04-94	AU 5165193 A	26-04-94
WO 9005780 A	31-05-90	AT 154636 T AU 645963 B AU 4668689 A DE 68928137 D DE 68928137 T EP 0447483 A ES 2104599 T JP 4506449 T	15-07-97 03-02-94 12-06-90 24-07-97 19-02-98 25-09-91 16-10-97 12-11-92
WO 9014432 A	29-11-90	US 5580753 A AT 147436 T AU 637620 B AU 5928990 A CA 2056997 A DE 69029657 D DK 473724 T EP 0473724 A ES 2099096 T JP 4506006 T US 5734037 A US 5414071 A	03-12-96 15-01-97 03-06-93 18-12-90 24-11-90 20-02-97 14-04-97 11-03-92 16-05-97 22-10-92 31-03-98 09-05-95
WO 9617925 A	13-06-96	AU 4639396 A CA 2206488 A FI 972390 A NO 972455 A	26-06-96 13-06-96 05-06-97 06-08-97
US 5536637 A	16-07-96	US 5712116 A	27-01-98
WO 9707198 A	27-02-97	US 5707829 A AU 6712396 A AU 6768596 A EP 0839196 A WO 9704097 A	13-01-98 18-02-97 12-03-97 06-05-98 06-02-97

Information on patent family members

PCT/US 97/19590

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)